Clinical Digest: Recent Clinical Trials on Hepatitis (2026-04)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to Hepatitis. These trials are organized by their release dates for your convenience. (Last updated on: 2026-04-06)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on Hepatitis (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on The Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort. The cohort will include high-risk populations for hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) from multiple centers nationwide, who meet the criteria of traditional Chinese medicine syndrome differentiation as Qi-zhi-xue\_yu syndrome and have an aMAP score \>60 points. The objective is to evaluate whether combining Bie-jia-ruan-gan with standard anti-hepatitis B virus therapy can further reduce the incidence of HCC in this high-risk population. |
NANFANG HOSPITAL SOUTHERN MEDICAL UNIVERSITY | 2026-03-18 |
| 2 | Study on The Prevention of Recidivism and The Consequences of Sexual Violence Suffered By Female Asylum Seekers in France PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Women seeking asylum (WSA) are overexposed to sexual violence (SV) in their countries of origin, along migration routes, and within host countries. This overexposure does not cease upon arrival in host countries; on the contrary, the first months following arrival are characterised by heightened vulnerability, with an increased incidence of sexual violence, particularly among women with a prior history of victimisation. Sexual violence has major consequences on physical health, mental health, quality of life, and healthcare utilisation, and generates substantial individual and societal costs. International organisations, including the United Nations High Commissioner for Refugees, … |
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | 2026-03-19 |
| 3 | Double-blinded Placebo-controlled Multi-center Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. A total of 150 subjects are planned to be enrolled. After passing the screening, they will be randomly assigned to the L47 group or the placebo group at a ratio of 2:1, with liver cirrhosis and subjects’ regional distribution as stratification factors. The two groups will receive hepratide (2.1 mg/day) or placebo, respectively. Upon completion of the 48-week double-blind treatment phase, all subjects in each group can enter the open-label treatment follow-up phase, … |
SHANGHAI HEP PHARMACEUTICAL | 2025-12-30 |
| 4 | Molecular and Cellular Characterization of MALT Lymphoma Across Anatomical Sites: Integrative Transcriptomic and Epigenetic Approaches PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an slow growing malignancy characterized by marked biological and clinical differences across different anatomical sites. Using participants’ samples and clinical information, this observational and non-interventional research aims to generate a comprehensive molecular and cellular atlas of MALT lymphoma. The results will enable the identification of biologically meaningful tumor subtypes, microenvironmental niches, and candidate biomarkers with potential relevance for the diagnosis, prognosis, and therapy of MALT lymphoma. |
MAURILIO PONZONI; | 2026-02-12 |
| 5 | Non-randomized, Phase II, Open-label Study for Efficacy and Safety of Everolimus in Relapsed or Refractory Hemangioendothelioma and Other ISSVA Group I or II Vascular Malformation and Neoplasms PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background and Objectives Vascular anomalies are a heterogeneous group of disorders classified into vascular tumors and vascular malformations according to the ISSVA classification. Although most follow a benign course, a subset causes serious complications including organ dysfunction, chronic pain, thrombocytopenia, and hemorrhage. Kaposiform hemangioendothelioma (KHE) complicated by Kasabach-Merritt Phenomenon (KMP) carries a mortality rate of 14-24%. Surgical resection is the primary treatment when organ damage is not anticipated; however, when surgery is not feasible, pharmacologic therapy is considered. Agents such as interferon, corticosteroids, vincristine, cyclophosphamide, and propranolol have been used with variable efficacy, … |
YONSEI UNIVERSITY | 2026-03-17 |
| 6 | Assessment of Cardiac Problems in Children With Chronic Liver Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic liver disease (CLD) in children can sometimes lead to complications in other parts of the body, including the heart. The primary purpose of this observational study is to assess the presence and type of cardiac problems in children who have been diagnosed with chronic liver disease. Researchers will observe children under the age of 18 who are receiving care at the gastroenterology and hepatology unit at Assiut University Children Hospital. Participants will undergo standard medical evaluations to check both their liver and heart health. These evaluations include: * A detailed medical history and thorough physical examination * Routine blood tests to check liver function, kidney function, coagulation, and electrolytes * Abdominal imaging, such as an ultrasound, to look at the liver. * An electrocardiogram (ECG) to check the heart’s electrical activity and rhythm, including measuring the QTc interval. * An echocardiogram to look at the structure of the heart and check how well its chambers and valves are functioning. The study aims to identify specific heart conditions that can be associated with severe liver disease, such as portopulmonary hypertension, cirrhotic cardiomyopathy (changes in the heart muscle’s function), and electrical repolarization abnormalities. Children who already have known congenital heart disease or a history of other heart problems will not be included in the study. |
ANDREW GAMAL THABET; | 2026-03-30 |
| 7 | Prospective Study of Changes in Peripheral Blood Effector Tumor Antigen-Specific T Cells for Predicting Efficacy of Chemoimmunotherapy in Non-Small Cell Lung Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to explore whether changes in peripheral blood effector tumor antigen-specific T cells (ETASTs) can predict treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC) receiving chemoimmunotherapy. The study aims to: * Evaluate the relationship between ΔETAST levels (baseline to cycle 2) and progression-free survival * Compare the predictive performance of ΔETASTs with traditional biomarkers (PD-L1, … |
WEIBIAO ZENG; | 2026-02-06 |
| 8 | Modulation of Gut Microbiota Composition and Gut Permeability Profiles By Multispecies Synbiotic Supplementation in Hemodialysis Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic kidney disease (CKD) patients undergoing maintenance hemodialysis experience profound alterations in their gut microbiota, leading to dysbiosis and increased gut permeability. This disruption facilitates the translocation of endotoxins and gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate into the systemic circulation, contributing to heightened systemic inflammation, cardiovascular disease risk, and accelerated CKD progression. Synbiotic supplementation, particularly multispecies formulations, has emerged as a promising therapeutic strategy to restore gut microbial balance, enhance intestinal barrier integrity, … |
TUNGS’ TAICHUNG METROHARBOUR HOSPITAL | 2026-03-10 |
| 9 | A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection. Eligible participants will be randomized 1:1:1 to one of three groups: libevitug 20 mg/kg group , libevitug 10 mg/kg (N=50) group, or a control/delayed treatment group (N=50). The treatment groups will receive intravenous libevitug every 2 weeks for 96 weeks, while the control group will be observed for the first 48 weeks and then receive libevitug 20 mg/kg Q2W for 48 weeks starting from Week 48. |
HUAHUI HEALTH | 2026-03-30 |
| 10 | A Multi-Center, Single-Arm, Open-Label, Prospective, Phase 4 Study to Investigate The Safety and Efficacy of Rapidly Restarting Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Viremic and Virologically-Suppressed Male and Female HIV-Positive Patients Aged ≥18 Years Who Are Treatment-Experienced and Returning to Care After Experiencing A Treatment Interruption of ≥12 Weeks PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person’s health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, … |
JESSICA ALTAMIRANO; | 2026-03-31 |
| 11 | A Phase 1b, Open Label, Single and Multiple Ascending Dose-escalation Study to Assess The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Subcutaneous Adenylosuccinic Acid (ASA) in Two Siblings With Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of ASA-001 in two adults diagnosed with ADSS1 deficient myopathy. The main questions it aims to answer are: * Whether ASA-001 can be safely administered to ADSS1 deficient myopathy patients; * Whether daily treatment with ASA-001 provides benefit or slows progression of disease. Participants will: * Take ASA-001 every day for 8 months; * Visit the clinic once every 2 weeks for check-ups and tests |
PERRY B SHIEH; | 2026-02-17 |
| 12 | Non-invasive Predictors of Esophageal Varices in Pediatric Portal Hypertension and Their Correlation to Upper Endoscopic Findings PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study: * To evaluate the diagnostic accuracy of non-invasive markers in predicting the presence and grading of esophageal varices in children with portal hypertension. * To correlate these non-invasive markers with the severity of portal hypertension and the grade of esophageal varices to identify patients at high risk of bleeding. * To propose a defined protocol for screening esophageal varices in those children. |
MENNAT-ALLAH HESHAM ABDELRAHEEM; | 2026-03-23 |
| 13 | A Single-Arm, Open-Label, Multicenter Phase III Clinical Trial to Evaluate The Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a single-arm, multicenter, open-label Phase III clinical trial to evaluate the safety and tolerability of high-dose hydronidone capsules in patients with hepatic fibrosis and cirrhosis. Eligible participants will be sequentially enrolled to receive hydronidone capsules 120 mg three times daily (TID) for 28 consecutive days. Participants will return to the hospital on Day 28 after the first dose for a follow-up safety assessment. All adverse events (AEs) and concomitant medications must be recorded during the study period. Participants who complete the Day 28 follow-up visit are considered to have completed the study. |
BEIJING CONTINENT PHARMACEUTICAL | 2026-03-31 |
| 14 | Sequencing-Based Tracking of Entecavir Resistance-Associated Mutations in Chronic Hepatitis B Patients: A Multicenter Observational Study (STREAM) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage. Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations. By analyzing viral genetic material from blood samples using advanced sequencing technology, … |
YAŞAR BAYINDIR; | 2026-03-09 |
| 15 | A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial Evaluating The Safety of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This trial employs a single-arm, open-label, multicenter clinical trial design. All study participants who meet the inclusion/exclusion criteria will receive Hydronidone treatment for 4 weeks. The study includes a screening period (up to 21 days) to assess the eligibility of participants. Eligible participants will enter the treatment period and receive Hydronidone capsules at a dosage of 270 mg TID (30 mg/capsule, 3 capsules each time, three times daily, … |
BEIJING CONTINENT PHARMACEUTICAL | 2026-02-18 |
| 16 | An Open-label, Single-arm Clinical Study to Evaluate The Safety of Hydronidone Capsules in Patients With Liver Fibrosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, single-arm study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver fibrosis . Approximately 200 subjects will be enrolled, all of whom will receive hydronidone capsules three times daily, with three capsules per dose, resulting in a total daily treatment dose of 270 mg. The medication will be administered orally half an hour before meals for a total of 28 days. |
BEIJING CONTINENT PHARMACEUTICAL | 2026-04-02 |
| 17 | MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels AMong Congolese PregnAnt WoMen Attending to Ante Natal Care Consultations PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis. |
MAINDO ALONGO; | 2026-02-05 |
| 18 | VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in A Medical Intensive Care Unit PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Shock is a common and serious cause of admission to intensive care. Vascular filling is one of the cornerstones of shock treatment, aimed at increasing cardiac output and restoring adequate organ perfusion through rapid intravenous administration of a solution. However, this vascular filling can be accompanied by venous congestion, which can be harmful. Fluid administration must therefore be sparing and carefully considered. However, it is difficult to assess the correct amount of intravenous fluid to inject. Multi-site venous ultrasound (inferior vena cava, suprahepatic vein, portal vein, renal vein), recently published under a score called VExUS, … |
HADRIEN WINISZEWSKI; | 2026-02-27 |
| 19 | Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement: A Randomized, Placebo-controlled, Double-blinded Multicenter Superiority Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: ANCA-associated vasculitis (AAV) is a rare auto-immune disease, with high mortality in the absence of treatment. There is still an unmet need to define new treatment strategies to reduce drug side effects, as well as to reverse rare cases of refractory AAV and improve the kidney response to improve the long-term outcomes. Severe forms of AAV-related necrotizing and crescentic rapidly progressive glomerulonephritis (RPGN) (i.e. estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²) are associated with higher mortality, higher incidence of infections, and long-term consequences including chronic kidney disease (CKD) with subsequent complications (end-stage kidney disease (ESKD) requiring dialysis, ... |
UNIVERSITY HOSPITAL TOULOUSE | 2026-01-28 |
| 20 | A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a pilot study to determine the safety and efficacy of a novel adjuvanted hepatitis B virus (HBV) vaccine formulated as a potential therapeutic vaccine against chronic HBV infection. An ongoing human clinical trial of this HBV vaccine in a prophylactic setting has confirmed this vaccine to be more effective at inducing seroconversion as measured by development of Hepatitis B surface antibody (HBsAb) in poor responder subjects than the standard alum-adjuvanted HBV vaccine, providing promise that this new vaccine may also be able to induce HBV viral control and/or seroconversion in chronically infected subjects |
DIMITAR SAJKOV; | 2025-09-22 |
| 21 | A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the safety and antibody (germ fighters) response of the experimental (investigational) vaccine against HCV when injected into the arm of healthy adults. |
MICHAEL HOUGHTON; | 2026-02-06 |
| 22 | Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to determine the effect of electroacupuncture on central obesity and fatty liver in postmenopausal women. |
MOHAMED ABDEL HAMID ELGAEDY; | 2026-02-27 |
| 23 | The Effect of Consecutive Skin-to-Skin Contact Applied By The Mother and Father on Breastfeeding Parameters and Bonding in Babies Born By Cesarean Section PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled study aims to evaluate the effect of consecutive skin-to-skin contact applied by the mother and father on breastfeeding parameters and parent-infant bonding in babies born by cesarean section. The study includes two groups: an intervention group receiving consecutive skin-to-skin contact by the father followed by the mother, and a control group receiving routine postnatal care. Breastfeeding success and parental bonding will be assessed using validated measurement tools during the early postnatal period and follow-up. |
PARIA MOHAMMADIASL; | 2026-02-13 |
| 24 | Phase I/II Study of The Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection (acute or chronic) with or without HIV and to evaluate safety for their infants through 10 weeks postpartum. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-01-29 |
| 25 | A Phase 2b/3, Open-Label, Multicenter Trial Evaluating The Efficacy and Safety of Switching to Brelovitug for The Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD). |
MIRUM PHARMACEUTICALS | 2026-04-02 |
| 26 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed By CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Why is this study conducted? The purpose of this study is to improve the treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer (LARC). In recent years, with the combination of neoadjuvant chemoradiotherapy and immunotherapy, some progress has been made in the treatment of rectal cancer, but there are still problems of regional recurrence and distant metastasis. Therefore, developing new treatment strategies for these patients is particularly important. The treatment of rectal cancer usually involves surgery, radiation therapy, … |
PENGYU CHANG; | 2026-04-01 |
| 27 | A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of Single and Multiple Ascending Doses of IB-001 in Healthy Participants and Participants With Chronic Hepatitis B PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will examine the safety and tolerability of single and multiple doses of IB-001, and will be conducted in two parts: Part A: SAD study in approximately 60 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB). |
EDWARD GANE; | 2026-03-05 |
| 28 | Oral-Periodontal Evaluation and Assessment of Biomarkers in Oral Fluids in Patients With Hepatitis B+D Treated With Bulevirtide PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls. |
RESEARCH CENTER OF PERIODONTAL SYSTEMIC INTERACTIONS | 2026-03-25 |
| 29 | Syndemic Triple HIV/HBV/HCV Virus Screening Via EMR Automation at Primary Care Clinics PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Design: This will be a within-subjects repeated-measures design, testing an electronic medical record pop-up alert linked to order panels for screening blood tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Study participants will be primary care providers. For each participating provider, their encounter will be randomized to either control (no alert; no changes to EMR interface) or an alert with triple-testing order panel intervention arm (alert linked to order panel with screening tests for all three bloodborne viruses (BBVs) selected by default; … |
MAMTA K. JAIN; | 2025-12-15 |
| 30 | A Phase I Pharmacokinetic Study of Hydronidone Capsules in Patients With Varying Degrees of Hepatic Impairment and Normal Hepatic Function PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal hepatic function matched for sex, age, and BMI. The administration method is a single oral dose of 90 mg hydroxynidone capsules under fasting conditions. Participants meeting the inclusion criteria with corresponding degrees of hepatic impairment and those with normal hepatic function will be enrolled. Each group will complete the study with 10 participants. Matched participants will be comparable in terms of sex (±1 participant per sex), mean age (±10 years), … |
BEIJING CONTINENT PHARMACEUTICAL | 2026-02-12 |
| 31 | Multicentric Study on Indigenous and Affordable Microspheres for Selective Internal Radiation Therapy (SIRT) of Unresectable Liver Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortality.HCC remains the leading causes of cancer-related deaths worldwide, due to late diagnosis. Although local-stage liver tumors are curable with tumor resection or livertransplantation, 65-70% of diagnosed cases are not suitable for resection due to large or multifocal lesions. For these patients, local therapies such as transcatheterarterial chemoembolization (TACE) or selective internal radiation therapy (SIRT) are appropriate at intermediate stages. In cases of advanced and metastatic livertumors, … |
JAYA SHUKLA; | 2026-03-12 |
| 32 | A Phase 2 Multi-center, Randomized, Open-label Study to Assess The Efficacy and Safety of AHB-137 in Nucleos(t)Ide Analogue-treated Participants With HBeAg Negative Chronic Hepatitis B in The Asia Pacific Region PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs. |
AUSPERBIO THERAPEUTICS | 2026-01-27 |
| 33 | Development of Novel Diagnostics That Use Point-of-care Lateral Flow Testing Technology for Non-invasive, Individual Assessment of Antibody Protection to Tetanus and Vaccine Need PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to design, develop and optimise a non-invasive, saliva sample-based point-of-care lateral flow test for use in low and middle income settings that can return a qualitative result on whether an individual has or has not immunity to tetanus within 10-15mins. If successful, this approach would not require blood sampling or laboratory facilities, empower personalised decision making on vaccine needs and support the development of population level data-driven public health policies. |
UNIVERSITY OF BIRMINGHAM | 2026-03-03 |
| 34 | Development of A Hepato-Splenic Microcirculatory Perfusion Model Using IVIM MRI to Rule Out High-Risk Varices in Patients With Compensated Hepatitis B-Related Cirrhosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Chronic hepatitis B (CHB)-related cirrhosis is a common cause of portal hypertension, which leads to the development of gastroesophageal varices (EGVs). High-risk varices (HRV) are associated with a higher risk of bleeding and require timely interventions. Endoscopy is the gold standard for diagnosing HRV but is invasive and not suitable for routine screening in large populations. Objective: This study aims to develop a noninvasive model based on hepatic and splenic microcirculatory perfusion parameters derived from intravoxel incoherent motion (IVIM) magnetic resonance imaging (MRI) to predict and rule out HRV in patients with compensated CHB-related cirrhosis receiving antiviral therapy. Methods: This observational, retrospective study will include patients with compensated CHB-related cirrhosis who have undergone both esophagogastroduodenoscopy (EGD) and IVIM MRI. Microcirculatory perfusion parameters will be extracted from IVIM images using a biexponential model, and their ability to predict HRV will be assessed. Outcomes: The study will validate the performance of the Hepato-Splenic Microcirculatory Perfusion Model (HSMP) in ruling out HRV compared to conventional noninvasive tests like APRI, FIB-4, and LSM. The model’s diagnostic accuracy will be evaluated with a focus on reducing unnecessary endoscopic procedures. Significance: If successful, this model could reduce the need for invasive endoscopy and improve the management of cirrhosis patients by providing a safer and more accessible screening tool for HRV. |
HONG YOU; | 2026-03-05 |
| 35 | PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Only patients suffering from a severe form of alcoholic hepatitis (Maddrey’s discriminant function greater than 32) require medical treatment. Oral prednisolone for 28 days is the only treatment which has been proven to improve short-term survival over placebo in patients with severe alcoholic hepatitis. However, prednisolone alone cannot be regarded as an ideal treatment because some patients still have a bad outcome despite being treated with corticosteroids. Response to treatment can be predicted by the Lille score, a simple tool that is calculated after 7 days of prednisolone course. The ideal binary cut-off of the Lille is 0.45, … |
UNIVERSITY HOSPITAL LILLE | 2026-01-20 |
| 36 | A Multicenter, Double-blind, Randomized, Parallel Group, Active-controlled, Dose-ranging Study to Assess Efficacy, Safety, and Pharmacokinetics of Combogesic® 325 in Adolescent Patients (Aged 12 to Less Than 18 Years) With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Combogesic® 325 contains a combination of ibuprofen and acetaminophen. The purpose of this study is to compare the pain relief effects of Combogesic® 325mg and acetaminophen and to evaluate the safety of Combogesic® 325mg in adolescents between the ages of 12 and \<18 years. What will the study involve for participants? * Participants will be randomly allocated to one of 3 treatment groups: * 3 tablets of Combogesic® 325, ... |
AFT PHARMACEUTICALS | 2025-11-05 |
| 37 | Efficacy of Ursodeoxycholic Acid Versus Corticosteroids for The Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period. The trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids. |
UNIVERSITY HOSPITAL MONTPELLIER | 2026-01-30 |
| 38 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIIc Clinical Study Evaluating The Long-term Treatment of Hepatic Fibrosis in Chronic Hepatitis B With Hydronidone Capsules PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study consists of a Screening/Baseline Period (4 weeks) and a Dosing/Observation Period (planned duration of 5 years, including a 52-week primary treatment phase and a 208-week long-term treatment phase). |
BEIJING CONTINENT PHARMACEUTICAL | 2026-02-17 |
| 39 | Evaluation on The Persistence of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell), Combined Live Attenuated Measles, Mumps and Rubella Vaccine and Freeze-dried Live Attenuated Hepatitis A Vaccine in Chinese Children: Up to 5 Years of Follow-up PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine. |
CHINA NATIONAL BIOTEC GROUP COMPANY | 2026-01-14 |
| 40 | RE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm SaFety and EffIcacy of TReatMent) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (\>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive. |
BAUSCH HEALTH AMERICAS | 2026-04-03 |
| 41 | HIV, Equity, and Addiction Training (HEAT) Program PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This project is a pilot study to determine the feasibility and acceptability of a telemedicine intervention for substance use disorder service delivery in diverse people living with HIV in Alabama. |
ELLEN EATON; | 2026-02-18 |
| 42 | A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug Vs Delayed Treatment for The Treatment of Chronic Hepatitis Delta Infection (AZURE-4) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment. |
MIRUM PHARMACEUTICALS | 2026-03-02 |
| 43 | Blinatumomab’s Outcome On Serologic Titers and Efficacy of Revaccination PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity. Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination. |
LAUREN APPELL; | 2026-02-20 |
| 44 | Efficacy and Safety of Entecavir With or Without Pegylated Interferon Α-2b in Children Aged 3 to 6 Years With Chronic Hepatitis B in The Immune-Clearance Phase (B-Young-Cure-2): A Multicenter, Open-Label, Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B. |
QING-LEI ZENG; | 2026-01-16 |
| 45 | Efficacy and Safety of Entecavir With or Without Pegylated Interferon Α-2b in Children Aged 3 to 6 Years With Immune-Tolerant Chronic Hepatitis B Virus Infection (B-Young-Cure-1): A Multicenter, Open-Label, Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with chronic hepatitis B virus infection. |
QING-LEI ZENG; | 2026-01-16 |
| 46 | Machine Learning for Prediction of Therapy Response in Autoimmune Hepatitis PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The 5th International Autoimmune Hepatitis Group (IAIHG) research workshop emphasized the integration of large clinical cohorts with artificial intelligence (AI) for enhanced prediction of therapy responses and outcomes in Autoimmune Hepatitis (AIH). This project aims to develop and validate machine learning (ML) models using data from the R-Liver registry and other international cohorts. After rigorous preprocessing to ensure data uniformity and quality, the investigators will identify and characterize factors influencing therapy response. They will then implement ML models to predict complete biochemical response (CBR) at 6 and 12 months, using five-fold cross-validation, … |
BASTIAN ENGEL; | 2026-01-30 |
| 47 | Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study in Phichit province, Thailand, aims to find and support adults born before 1992 who are at high risk for hepatitis B infection. Many people in this group were born before the universal hepatitis B vaccine was available and may not know they are infected. The study will invite nearly 240,000 eligible adults for free hepatitis B screening. Those who test positive will be linked to care at one of 12 district hospitals. Doctors will use simplified 2024 World Health Organization (WHO) guidelines to decide who needs treatment. Eligible individuals will receive a safe, … |
TAWASEK TAWANDEE; | 2025-12-02 |
| 48 | Introducing HCC Surveillance in The Central Denmark Region PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to investigate whether repeated 6-monthly screening for hepatocellular carcinoma (HCC) – called HCC surveillance – offered to selected patients with chronic liver disease can reduce HCC-related mortality by facilitating earlier detection of HCC. The screening procedure consists of two tests: an ultrasound examination of the liver and a blood sample to measure alpha-fetoprotein. Patients who screen positive on either examination will be offered standard work-up for HCC, typically beginning with a CT-scan. In the study HCC surveillance will be offered to all patients with compensated non-viral cirrhosis residing in the Central Denmark Region, … |
PETER JEPSEN; | 2026-03-13 |
| 49 | A Prospective, Multi-center, Randomized Parallel Controlled Clinical Study on The Efficacy and Safety of Protein A Immunoadsorption and Intravenous Immunoglobulin in The Treatment of Guillain-Barre Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Guillain-Barre syndrome is an immune-mediated acute inflammatory peripheral neuropathy. The currently effective treatment methods include intravenous immunoglobulin and plasma exchange. Immunoadsorption has been widely used to treat immune-related diseases. There are currently no prospective large-sample clinical trials of immunoadsorption therapy for Guillain-Barre syndrome. The neuro-intensive care unit of the First Affiliated Hospital of Zhengzhou University is preparing to carry out a prospective, multi-center, … |
WANG MIAO; | 2025-03-12 |
| 50 | Multi-modal, Multi-parametric Liver Imaging for Ultrasound-based Stratification of Patients With MAFLD PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tissue elasticity and viscosity correlate with pathology. These tissue properties are typically evaluated subjectively using palpation. The purpose of elastography is to provide an objective elasticity image that is equivalent to the remote palpation of tissue. The investigators have developed elastography imaging systems based on ultrasound and magnetic resonance imaging and have applied them previously to prostate imaging, breast imaging in patients and liver imaging in healthy volunteers. A first objective of this study is to compare the investigators’ ultrasound shear wave absolute vibro-elastography (S-WAVE) technology with the existing clinical standard, FibroScan, … |
SEPTIMIU E. SALCUDEAN; | 2026-01-28 |
| 51 | Prospective Cohort Study on Pegylated Interferon Alfa-2b in Improving Clinical Cure Rate of Adolescent and Pediatric Patients With Chronic Hepatitis B Virus Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: In this study, comparisons will be made between the treatment group (which will receive pegylated interferon alfa-2b treatment) and the observation group (which will receive no drug treatment or be treated with nucleos(t)ide analogs). The primary objectives are to address the following questions: compare the efficacy evaluation indicators (with clinical cure rate as the primary one) between the pegylated interferon alfa-2b treatment group and the observation group; assess whether pegylated interferon alfa-2b treatment improves the clinical cure rate in patients with chronic hepatitis B virus (HBV) infection aged 3 years and above but under 18 years (adolescents and children); … |
YONGYIN LI; | 2025-11-17 |
| 52 | Study on Novel Immunomodulatory Therapeutic Regimens for Clinical Cure of Chronic Hepatitis B and Efficacy Prediction PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Achieving clinical cure, defined as hepatitis B surface antigen (HBsAg) seroclearance, represents a major research focus and an ideal therapeutic goal for chronic hepatitis B (CHB). A significant challenge in CHB management lies in promoting clinical cure, reducing relapse, and progressing towards complete cure. Studies have found that in patients who achieve HBsAg seroclearance following peginterferon alfa (PegIFNα) therapy, the seroconversion of anti-HBs and its attainment to a certain level are crucial for minimizing relapse. Strategies to promote anti-HBs seroconversion include active immunization (hepatitis B vaccine) and passive immunization (hepatitis B immunoglobulin, … |
BO FENG; | 2026-01-09 |
| 53 | Rapid HIV, Hepatitis C, and Syphilis Screening in A Rural Street Medicine Clinic in West Virginia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: West Virginia faces rising rates of HIV, hepatitis, and syphilis, particularly among individuals experiencing homelessness, substance use, and mental health challenges. Traditional blood-draw testing for these infections is often hindered by mistrust, logistical barriers, and delays in results. This study, conducted by the West Virginia University (WVU) Street Medicine program, evaluates a rapid, point-of-care fingerstick test for HIV, Hepatitis C, and syphilis that provides results within 10-20 minutes during mobile clinic visits. Participants may choose rapid testing, traditional blood draw (which also includes Hepatitis B screening), … |
MADISON HUMERICK; | 2026-01-20 |
| 54 | Role of AST/ALT Ratio & MPV/Platelets Count Ratio in Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This retrospective study aims to evaluate the association between AST/ALT ratio and MPV/platelets count ratio with breast cancer in a case-control study. |
GEHAD SALAH EL-DIN SHAKER; | 2025-12-19 |
| 55 | Single-center, Prospective, Randomized Controlled Study of PT-MSCs Exosome Injection (Code: PT-MSCs-EVS-2023-1) in The Treatment of Chronic-to-acute Liver Failure PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this single-center, prospective, randomized controlled study is to evaluate the safety and efficacy of PT-MSCs Exosome Injection (code: PT-MSCs-EVS-2023-1) in treating patients with acute-on-chronic liver failure (ACLF). As an exploratory study with a small sample size, … |
LIANG PENG; | 2026-02-13 |
| 56 | A Multicenter, Randomized, Placebo-Controlled and Positive-Controlled Phase III Clinical Trial to Evaluate The Efficacy and Safety of TVAX-008 Injection in The Treatment of Chronic Hepatitis B PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, randomized, placebo-controlled (double-blind design) versus active-controlled (open-label design) Phase I clinical trial evaluating the efficacy and safety of TVAX-008 injection in subjects with chronic hepatitis B. |
GRAND THERAVAC LIFE SCIENCES NANJING | 2025-12-15 |
| 57 | TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for The Treatment of Unresectable Hepatocellular Carcinoma With Cirrhotic Portal Hypertension: A Multicenter, Simon Two-Stage, Single-Arm Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically significant portal hypertension (CSPH). CSPH not only limits treatment options and worsens prognosis but also leads to the frequent exclusion of such patients from pivotal clinical trials, resulting in a lack of high-level evidence for their management. Carvedilol, a non-selective beta-blocker, … |
WAN-GUANG ZHANG; | 2026-01-20 |
| 58 | Real-World Data on The Treatment of Lung Cancer Patients With The Immune-Checkpoint Inhibitor Tislelizumab – The ReWoLuTe Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice. |
RAOUL DE JONGE; | 2026-04-03 |
| 59 | A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label study with single- and multiple-ascending dose arms followed by a dose expansion arm. The primary objective of the study is to determine the safety and tolerability of CRMA-1001 in adult participants with Chronic Hepatitis B. In addition, the pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of CRMA-1001 will be evaluated. CRMA-1001 is an epigenetic gene therapy delivered via intravenous (IV) infusion. Up to four dose levels will be tested. Participants will receive a single or multiple doses of CRMA-1001 and will remain on antiviral therapy during the dosing process. |
NCHROMA BIO | 2026-01-29 |
| 60 | VIROMARKERS GA N.101194735 – CMV and TTV Biomarkers Study Protocol PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study is one of the researches carried out in the VIROMARKERS Project. The project VIROMARKERS is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194735. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bio, MedTech Europe, Vaccines Europe, and Roboscreen. To date, the virological surveillance for CMV replication relies basically on the quantification of CMV-DNA in blood or plasma by using Real-Time PCR assays, and CMV-DNAemia is known to correlate with both CMV-related disease and non-relapse mortality \[Ljungman, 2025\]. However, … |
VALENTINA SVICHER; | 2025-12-16 |
| 61 | Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules As Enhancers of Bone Formation in Bone Grafting PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate bone formation in grafts in terms of its quality (density), quantity (volume) and maturation obtained with the application of a tissue-engineered bone grafting compound containing concentrated autogenous cell-culture medium (CM) and a synthetic bone substitute. The present study was designed as an experimental prospective split-mouth randomized controlled clinical trial. After protocol approval by the Research Ethics Committee, a total of 20 consecutive participants in need of maxillary reconstruction aiming implant-supported oral rehabilitation will be invited to join the study. To collect autogenous adipose tissue-derived mesenchymal stem cells (hASCs), … |
EDUARDO ROLIM TEIXEIRA; | 2025-06-05 |
| 62 | Liver Affection in Pregnant Women at Sohag University Hospitals PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study investigates the prevalence, causes, and clinical outcomes of liver disorders among pregnant women attending Sohag University Hospital. It aims to identify the most common hepatic conditions occurring during pregnancy, evaluate their impact on maternal and fetal health, and assess the effectiveness of current diagnostic and management approaches. By analyzing clinical data, laboratory findings, and pregnancy outcomes, the study highlights the importance of early detection and proper management of liver diseases to reduce associated complications and improve overall maternal-fetal prognosis. |
EMAN ASHRAF SAAD AHMED; | 2025-12-23 |
| 63 | EPIC – A Phase 2, Randomized, Open-label, Multicenter, Controlled Study to Evaluate The Efficacy, Safety, and Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) in Melanoma or Non-Small Cell Lung Cancer (NSCLC) Patients With Immune-related Colitis Induced By Immune Checkpoint Inhibitor Therapy Who Have Inadequate Response to Steroids Related Papers Related Patents Related Grants Related Experts Highlight: The photoactivating agent UVADEX (methoxsalen) is used in conjunction with extracorporeal photopheresis (ECP) as an immunomodulatory therapy approved for the treatment of cutaneous T-cell lymphoma. ECP involves collecting whole blood from the patient, separating white blood cells (WBCs) via centrifugation, combining them with UVADEX, and then exposing them to ultraviolet A (UVA) light. All blood components, including the treated WBCs, are then returned to the patient. Immune Checkpoint inhibitor (ICI) therapy is used to treat different types of cancer, … |
THERAKOS | 2025-12-26 |
| 64 | Pattern of Congenital Heart Diseases and Developmental Evaluation in Children Below Two Years With Cholestasis at Assiut University Children’s Hospital PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Congenital heart diseases (CHDs) are common in infants with cholestasis due to shared prenatal and metabolic factors. This study aims to determine the frequency and types of CHDs and to assess physical and mental development in children below two years with cholestasis at Assiut University Children’s Hospital. |
SHIMAA AHMED MAHROS; | 2025-11-25 |
| 65 | A Study to Evaluate The Efficacy and Safety of Steroid Sparing Strategy in Immune Related Hepatitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A multi-centre, randomized, non-inferiority trial in patients with irH, randomized to receive either close surveillance with corticosteroid rescue therapy or early high dose corticosteroids. |
OMAR KHAN; | 2026-03-23 |
| 66 | Prevalence and Risk Factors Associated With Resistance to Antiviral Therapy in Egyptian Patients With Chronic Hepatitis B Virus Infection PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors. Understanding patterns of resistance will help improve treatment selection and optimize long-term management strategies for HBV patients. |
AMIRA MOHAMED ZIDAN; | 2025-12-10 |
| 67 | Prevalence of Hepatitis B and C Within The Chinese Community Residing in Milan PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to assess the effectiveness of targeted screening for Hepatitis B (HBV) and Hepatitis C (HCV) infections in adults aged 18 to 50 from the Chinese community residing in Milan. The main questions it aims to answer are: * Does community-based, culturally sensitive screening increase the detection of undiagnosed HBV and HCV infections in this high-risk population? * What is the level of adherence, satisfaction and awareness regarding rapid testing methods in this community? Participants will: * Receive pre-test counseling in Italian or Chinese with the help of an interpreter * Complete a brief, … |
FEDERICA INVERNIZZI; | 2025-11-21 |
| 68 | Very Low Dose, Add-on Prednisolone in Patients With Newly Diagnosed Rheumatoid Arthritis: A Randomised Placebo-controlled Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Objective To investigate the efficacy of prednisolone 4mg/day added to standard of care in newly diagnosed rheumatoid arthritis (RA) patients with active disease. Hypothesis Add-on prednisolone 4mg/day is efficacious compared to placebo in newly diagnosed RA patients with active disease. Design and subjects This is a 12-week, randomized, placebo-controlled, … |
HO SO; | 2025-12-02 |
| 69 | California Hub for HIV/STI/SUD Prevention Research With Reentry Populations PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The California Hub for HIV/SUD Prevention Research with Reentry Populations addresses the question: Can the evidence-based MEPS intervention be adapted and implemented at a range of organizations to effectively serve a wider range of clients? The Mobile Enhanced Prevention Support (MEPS) intervention was originally implemented in Los Angeles County and was proven successful in promoting biomedical HIV prevention (PrEP) uptake and preventative screenings in people who used drugs who recently left incarceration. MEPS is an evidence-based intervention for people with substance use disorders (SUD) that incorporates a client-centered planning session, including trained peer mentors, service utilization incentives, … |
NINA T. HARAWA; | 2026-04-03 |
| 70 | Prospective, Randomized, Controlled Clinical Study Comparing TAF Monotherapy Versus ETV Combined With TAF on The Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Study Objective: To compare the efficacy and prognosis of systemic cancer therapy between TAF monotherapy and ETV plus TAF combination therapy in patients with unresectable, advanced hepatitis-B-related hepatocellular carcinoma (HBV-HCC). Study Design: Prospective, interventional cohort study. Participants: Patients with histologically or radiologically confirmed unresectable, … |
CHAN XIE; | 2025-11-28 |
| 71 | Efficacy and Safety of Ablative Fractional CO2 Laser and Platelet-rich Plasma (PRP) With Microneedling for Treatment of Acne Scars: A Real-world Comparative Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Road traffic accidents (RTAs) remain a major public health concern worldwide and in Bangladesh, contributing significantly to injury, disability, and premature death. In resource limited settings like Bangladesh, it is crucial to understand the factors that influence survival following an RTA in order to develop effective prevention strategies and improve patient outcomes. Therefore, … |
AZMIREE BINTE ASLAM; | 2025-12-03 |
| 72 | Evaluation of Agreement Between The Handheld Elastography Device and ILivTouch for Multi-Position Liver Assessment in Chronic Liver Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This single-center cross-sectional study aims to evaluate the agreement between a handheld elastography device and the iLivTouch transient elastography system for the noninvasive assessment of liver fibrosis and steatosis in adults with chronic liver disease. The study compares liver stiffness measurement (LSM) and ultrasound attenuation parameter (UAP) obtained by both devices in the standard supine position, and further explores the feasibility and consistency of measurements performed in the sitting position. All participants will undergo paired examinations using both devices in two body positions (supine and sitting). Agreement between devices and between body positions will be assessed using Bland-Altman analysis, … |
HONG YOU; | 2025-11-21 |
| 73 | MitoQ (Mitoquinol Mesylate) to Ameliorate Vascular Function in Preeclampsia: A Novel Approach PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option. |
JENNIFER MCINTOSH; | 2025-11-14 |
| 74 | Use of Transient Elastography to Guide Immunosuppression Minimization Post Liver Transplantation PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease and cancer risk. Therefore studies are looking at safe ways to reduce or stop immunosuppression. An individual without autoimmune liver disease (these patients are at higher risk of rejection), without history of rejection, with normal blood tests (liver biochemistry, liver function, etc.) can be eligible for minimization of immunosuppression. A recent study showed use of fibroscan (an Ultrasound, … |
UNIVERSITY OF ALBERTA | 2026-01-08 |
| 75 | PREVENTION OF RECURRENCE OF CLOSTRIDIOIDES DIFFICILE COLITIS WITH URSODEOXYCHOLIC ACID (UCDA) AS A SUPPLEMENT TO STANDARD THERAPY PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C. diff colitis is a serious infection that can return after treatment, and researchers want to see if UDCA can reduce this risk. This study aims to answer three main questions. First, can UDCA help prevent C. diff from returning after standard treatment? Second, does adding UDCA to treatment lower the need for repeated antibiotic use? Third, … |
DANIEL STEIN; | 2025-10-09 |
| 76 | Clinico_Epidemiological Profile Of Acquired Aplastic Anemia Among Children At Assiut Governorate PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: 1. Assessment the clinical presentation and epidemiological profile of children with acquired aplastic anemia. 2. Determining the possible risk factors and associated conditions contributing to the development of acquired aplastic anemia. |
SARA RAMADAN HASSANEIN HASSAN; | 2025-12-02 |
| 77 | Quasi-Randomized Controlled Trial of Acceptance and Commitment Therapy for Chemsex Related Papers Related Patents Related Grants Related Experts Highlight: Quasi-randomized control trial of acceptance and commitment therapy (ACT) for chemsex. |
NICHOLAS C. BORGOGNA; | 2025-12-15 |
| 78 | Comparison of Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B at Birth Dose Using New Hepatitis B Bulk (Bio Farma), in Indonesian Infants Related Papers Related Patents Related Grants Related Experts Highlight: This bridging study is a randomized, double-blind, two arms parallel group, prospective intervention study. The primary objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma). |
EDDY FADLYANA; | 2025-06-05 |
| 79 | Exploratory Use of CMV Immunoglobulin in High Risk (D+R-) Transplant Recipients at The End of Antiviral Prophylaxis to Decrease The Risk of Late CMV Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant. |
CAMILLE N. KOTTON; | 2025-12-22 |
| 80 | A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA1211 Injection in Healthy Participants and Participants With Chronic Hepatitis B PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of SA1211 Injection in healthy volunteers (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in participants with chronic hepatitis B (CHB). The main questions it aims to answer are: What are the safety, tolerability, immunogenicity and PK characteristics of a single subcutaneous injection of SA1211 Injection in healthy volunteers (Part A)? What are the safety, tolerability, … |
YANHUA DING; | 2025-12-10 |
| 81 | A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as Autoimmune polyendocrine syndrome type-1 (APS-1), is a disease that causes the immune system to attack parts of a person s body. In some people, APECED attacks the small intestine; … |
MICHAIL S LIONAKIS; | 2025-12-11 |
| 82 | Vaccination Nudges Project: Behavioural Nudges From Pharmacists to Increase Influenza and Travel Vaccination Uptake: A Pragmatic Randomized Control Trial PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this individual-level pragmatic randomized policy trial is to learn about the impact of behavioural nudges via mailed letters on increasing influenza and travel vaccination uptake in Alberta, Canada. The primary outcome is the proportion of adults receiving influenza and/or travel vaccination. The secondary outcome is the number of stroke events in the 6 months following vaccination. As such, this research aims to answer two key questions: 1. Do behavioural nudges increase influenza and travel vaccination in Alberta? 2. If yes, … |
AMITY QUINN; | 2026-02-10 |
| 83 | A Clinical Study to Evaluate The Efficacy and Safety of HT-101 Injection Combined With HT-102 Injection in Patients With Chronic Hepatitis B PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy of HT-101 injection combined with HT-102 injection. |
SUZHOU HEPATHERA BIOTECH | 2025-11-24 |
| 84 | Worldwide Assessment of Deceased Donor Kidney Utilization: Disparities, Temporal Trends, and Outcomes PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: The persistent imbalance between kidney transplant demand and organ availability remains a major global challenge. Optimizing the utilization of kidneys from deceased donors is a critical strategy to expand the donor pool and increase access to transplantation. Previous studies have demonstrated substantial international differences in kidney acceptance and discard practices, with significant potential gains in allograft life-years through optimized utilization. However, major changes in allocation policies, donor characteristics, preservation technologies, and global events such as the COVID-19 pandemic may have altered contemporary utilization patterns. This study aims to characterize international trends in deceased donor kidney utilization, … |
ALEXANDRE LOUPY; | 2026-01-14 |
| 85 | HBV UnIversal Vs Point-Of-Care-based Antiviral TreatMent to Prevent Mother-to-child Transmission PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: To achieve global elimination of hepatitis B virus (HBV), it is crucial to eliminate HBV mother-to-child transmission (MTCT) by ensuring high coverage of birth dose vaccine and expanding the adoption of peripartum antiviral prophylaxis (PAP) by tenofovir. Current international guidelines require hepatitis B surface antigen (HBsAg)-positive pregnant women to undergo viral load (VL) quantification to identify those at high risk (VL ≥200,000 IU/mL) who should receive PAP. However, VL testing remains inaccessible in many low- and middle-income countries (LMICs), particularly in rural areas. Consequently, in the forthcoming guidelines, … |
ANRS EMERGING INFECTIOUS DISEASES | 2025-07-08 |
| 86 | Prospective Randomized Controlled Trial of Immunodynamics-Guided Optimization of Individualized Immunochemotherapy Infusion Timing in Driver Gene-Negative Advanced Non-Small Cell Lung Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate whether individualized sequencing of immunotherapy and chemotherapy based on immune dynamics can improve treatment outcomes in adults with advanced non-small cell lung cancer (NSCLC) without driver gene mutations. This study will also assess the safety and feasibility of different infusion strategies. The main questions it aims to answer are: Does optimizing the timing of PD-1 inhibitor infusion relative to chemotherapy improve the objective response rate (ORR)? Does individualized infusion sequencing enhance progression-free survival (PFS) compared to standard or fixed-delay administration? What safety concerns or immune-related adverse events occur with different infusion timing strategies? Researchers will compare three treatment strategies: Group A (Standard Concurrent Group): Immunotherapy and chemotherapy administered on the same day (D1). Group B (Fixed Delay Group): Chemotherapy on D1, followed by PD-1 inhibitor infusion on Day 3. Group C (Individualized Delay Group): Chemotherapy on D1, and PD-1 inhibitor infusion scheduled on D2-D6 based on daily immune monitoring. Participants will: Receive a PD-1 inhibitor (e.g., sintilimab, pembrolizumab, camrelizumab) combined with platinum-based chemotherapy. Attend clinic visits for regular immune monitoring, imaging assessments, and safety checks during each treatment cycle. Undergo blood tests to evaluate immune biomarkers (e.g., CD8⁺PD-1⁺ T cells, MDSC, Treg、IFN-γ、NLR、ALC、CRP) to guide individualized treatment decisions. |
LIANG BIN; | 2025-09-24 |
| 87 | Role of USP35 in The Detection of Ferroptosis in Juvenile Autoimmune Hepatitis: An Immunohistochemical Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: 1. To evaluate the immunohistochemical expression of USP35 in cases of juvenile autoimmune hepatitis and control cases. 2. To correlate this with the level of necro-inflammation and extent of fibrosis using Massion’s trichrome stain in cases of juvenile autoimmune hepatitis. |
MARIAM MOHAMED RASHWAN MOHAMED; | 2025-03-26 |
| 88 | A Single-Center, Open-Label, Randomized, Crossover Phase I Clinical Study to Evaluate The Pharmacokinetics and Bioequivalence of Two Different Formulations of HMPL-523 Acetate Tablets in Chinese Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Two formulations containing the same active pharmaceutical ingredient are considered bioequivalent if their relative bioavailability (rate and extent of drug absorption) falls within acceptable predetermined limits after administration at the same molar dose. Formulations with bioequivalence are considered to act comparably in vivo, i.e., similar in terms of safety and efficacy. This study aims to evaluate the pharmacokinetic (PK) profile and bioequivalence of the original and modified formulations of HMPL-523 acetate tablets in healthy participants to bridge the safety and efficacy of the modified formulation of HMPL 523 acetate tablets in humans. |
HUTCHMED | 2026-02-12 |
| 89 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study involves patients that have a cancer called diffuse large B cell lymphoma (DLBCL), Natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma). Patients’ lymphoma has come back or not gone away after treatment. A previous research study at Baylor combined two ways of fighting disease: antibodies and T cells. Antibodies are proteins that bind to bacteria, viruses and other foreign substances to prevent disease. T-cells are special infection-fighting white blood cells that can kill tumor cells or cells infected with bacteria and viruses. Both have shown promise treating cancer, … |
PREMAL LULLA; | 2025-11-13 |
| 90 | Analysis of Risk Factors Affecting Mesenchymal Stem Cells Efficacy in Hepatitis B Related Acute-on-chronic Liver Failure PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Mesenchymal stromal cells (MSCs) are potential therapy for many diseases, with the ability of tissue regeneration, repair and immunomodulation. Acute-on-chronic liver failure (ACLF) is a severe disease with high mortality. Previous studies showed that MSCs can improve the outcomes of Hepatitis B virus (HBV)-related ACLF patients. However, there are still some ACLF patients who have not benefited from MSC treatment. Thus, … |
LIN BINGLIANG; | 2025-11-28 |
| 91 | Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH. |
MUHAMMAD UMAR; | 2025-12-03 |
| 92 | Augmentation of Humoral Immunity Using Toll-Like Receptor (TLR) 9 Adjuvanted HBV Surface Antigen to Enhance Anti-HBSAg Response PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if HEPLISAV-B, a vaccine that is approved to prevent hepatitis B infection in people that are not already infected, is safe in people already chronically infected with hepatitis B. The main quiestions it aims to answer are: 1. Is HEPLISAV-B safe in people with chronic hepatitis B? 2. What side effects, if any, could HEPLISAV-B cause in people with chronic hepatitis B? 3. How does HEPLISAV-B affect the cells that fight chronic hepatitis B? Participants will: * Receive HEPLISAV-B as an injection in the muscle, one injection every 4 weeks, … |
LYDIA TANG; | 2025-10-20 |
| 93 | Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL. |
GOVIND BHAGAT; | 2026-01-16 |
| 94 | Evaluation of The Hepatoprotective Effects of A Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection. The study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment. Participants will: Take the investigational supplement or active control daily for 12 weeks. Attend clinic visits every 4 weeks for laboratory testing and clinical evaluations. |
UNIVERSITY OF GUADALAJARA | 2026-03-23 |
| 95 | GPC-3 Chimeric Antigen Receptor T Cells FOR Recurrent GPC-3 Positive Glioblastoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T-cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat participants with cancers. They have shown promise, … |
GANESH RAO; | 2026-01-28 |
| 96 | Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Immunotherapy is a therapeutic strategy aimed at inducing the immune system to identify and combat cancer cells and, alongside the evident clinical success observed in many patients, a specific toxicity profile has emerged, associated with the modulation of the immune system achieved with this type of drugs, known as Immune-Related Adverse Events (irAEs). irAEs encompass a highly heterogeneous spectrum of autoimmune manifestations that can potentially involve any organ or system, occurring in \~ 80% of patients treated with anti-CTLA-4 agents and in \~ 60-70% of patients treated with PD-1/PD-L1 inhibitors. However, … |
ROBERTO FERRARA; | 2025-09-30 |
| 97 | Optimizing Pan-Viral Screening and Linkage to Treatment and Vaccination Among GBMSM and Trans Women in Spain, Including PrEP Users and Those Awaiting Access: An Online Self-Sampling Pilot Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, with major reductions in hepatitis B and C incidence and mortality. However, hepatitis C virus (HCV) transmission has increased among gay, bisexual, and other men who have sex with men (GBMSM), especially those living with HIV. Practices such as chemsex, particularly involving injection drug use, have contributed to this rise. Hepatitis B virus (HBV) also remains a public health challenge due to the potential for chronic infection and severe liver damage. Hepatitis D virus (HDV), which requires HBV co-infection, … |
FUNDACIÓ INSTITUT GERMANS TRIAS I PUJOL | 2025-07-25 |
| 98 | Phase Ib/II Study of LW231 in Patients With Chronic Hepatitis B: Evaluation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy With Multiple-Dose, Dose-Escalation, and Combination With Nucleos(t)Ide Analogs (NUC) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase Ib/II, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B virus (HBV) infection. The trial will include multiple-dose regimens of LW231 and assess LW231 in combination with NUCs. |
SHANGHAI LONGWOOD BIOPHARMACEUTICALS | 2025-10-02 |
| 99 | Referral Attivo Delta, Dallo Screening Alla Presa in Carico PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of the Active Delta Referral Project is to estimate the prevalence of anti-HDV positivity among HBsAg-positive patients hospitalized in the Department of Medicine at ASST Papa Giovanni XXIII in Bergamo, as well as among patients at the SerD and the Prison Healthcare Unit of the same ASST, following the introduction of the new methodology in 2025, and to compare these findings with existing estimates for outpatients. |
ALESSANDRO LOGLIO; | 2026-01-05 |
| 100 | Measurement of Hepatocyte TREM-1 Expression Level to Evaluate Its Intrinsic Performance and Prognostic Value in Severe Symptomatic Alcohol-related Hepatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background \& Rationale Severe alcohol-related hepatitis (SAH) is a serious condition with a 3-month mortality rate of \~30%. Diagnosis and prognosis are complex due to non-specific and insensitive clinical, biological, and histological indicators. Corticosteroids-the only validated treatment-are only effective in 50% of cases and can worsen outcomes in non-responders by promoting infections. Liver transplantation remains a limited option due to organ scarcity and patient eligibility. TREM-1, a pro-inflammatory receptor, has shown promise in inflammatory liver diseases. Its expression in hepatocytes may serve as a biomarker to better classify patients, guide treatment, … |
HAGHNEJAD VINCENT; | 2025-09-16 |
| 101 | Assessment of Lymphocyte Subset Functions in Children Admitted to Assiut University Children Hospital With Acute Hepatitis A Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Hepatitis A Virus (HAV) is a public health concern in Egypt, especially among children. Historically highly endemic, recent studies suggest a changing epidemiology. While improved socioeconomic conditions have reduced its spread, HAV remains prevalent, with over 50% of Egyptians exposed by age 15. Infection is often asymptomatic or mild in children but can be more severe with age. Prevention relies on improved sanitation and hygiene, with vaccin and recov |
MARTINA ADEL ATTIA MASSOD; | 2025-04-24 |
| 102 | Impact of Clinico-hematological and Molecular Characteristics on Treatment Outcomes of Chronic Lymphocytic Leukemia Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: the goal of this study is To describe the clinical, hematologic, and cytogenetic characteristics of CLL cases. The main questions it aims to answer are: 1. what is the impact of cytogenetics abnormalities \[e.g., IGHV mutation status, del(17p)\] on patients’ treatment response? 2. what is th correlation between clinical and hematological characteristic with patients’ outcome. All participants will be subjected to history taking , Physical examination. and Laboratory investigations (Complete blood picture Cytogenetic profiles: del(17p) molecular study :IGHV mutation status). |
SAWSAN ABDELLLAH; | 2025-09-09 |
| 103 | 6 Months of Bedaquiline, Delamanid, Linezolid and Levoffoxacin in RR-TB Patients in Hubei Province PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to compare the efficacy and safety of a 6-month all-oral regimen including Bedaquiline (BDQ,B), Delamanid (DLM,D), Linezolid (LZD, L), and Levofloxacin (LFX,L) to the the standard long – course treatment regimen within the Chinese population. The main questions it aims to answer are: Is the efficacy of short regimen non-inferior to standard regimen? Is the short regimen safe enough to replace the standard regimen? Participants will: Be given with either short or standard regimen for RR-TB treatment Be asked to complete the scheduled visit as planned. |
YAN HU; | 2025-09-30 |
| 104 | The Effect of White Noise and Buzzy Use on Pain During Infant Vaccination: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled trial aims to evaluate the effectiveness of two non-pharmacological methods-white noise and the Buzzy device-in reducing pain experienced by infants during routine vaccination. Infants are known to feel pain, and untreated or poorly managed pain during early life may lead to negative short- and long-term outcomes. Therefore, identifying effective, safe, and easy-to-apply pain-reducing strategies is essential for improving infant comfort and supporting evidence-based nursing practices. |
BURCU SELVI CALSIKAN; | 2025-12-23 |
| 105 | Lung Transplantation Using Hepatitis B Positive Donors to Hepatitis B Negative Recipients Using Ex-Vivo Treatment of Organs: A Safety Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals |
UNIVERSITY HEALTH NETWORK TORONTO | 2025-11-17 |
| 106 | Changes in Bile Acid Profile and Gut Microbiota in Patients Undergoing Treatment With Bulevirtide for Hepatitis Delta Virus Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: HDV is an RNA virus that infects only in the presence of HBV, affecting about 13% of HBsAg carriers. In Italy, prevalence ranges from 3.2% to 9.3%. It increases the risk of cirrhosis, fulminant hepatitis, and HCC, particularly in high-risk groups (HIV, HCV, drug users, dialysis patients). Until 2020, pegIFN was the only therapy; since 2022, bulevirtide (BLV) has been available, blocking viral entry into hepatocytes and reducing HDV RNA and liver stiffness, with efficacy in 45-48% of patients, … |
PONZIANI FRANCESCA ROMANA; | 2026-02-24 |
| 107 | Genetic Determinants of Myocarditis Induced By Immune-checkpoint Inhibitors PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Immune checkpoint inhibitors (ICI) are active in multiple cancers. Their main drawback is the incidence of immune related adverse events; among which ICI-myocarditis (ICIM) is rare but can be the most life-threatening (up to 50% lethal). ICIM is due to ICI unleashing cytotoxic auto-reactive T-cells recognizing a culprit target antigen located on muscles and destroying them. Most often, ICIM occurs within a systemic ICI-myotoxicity, with peripheral muscular involvement (ICI-myositis), … |
JOE ELIE SALEM; | 2025-11-21 |
| 108 | Pilot Study of At Home Ammonia Monitoring in Patients With An Inborn Error of Ammonia Metabolism PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to learn if people with certain ammonia metabolism disorders will measure their ammonia levels at home. The main question it aims to answer is: • Will participants measure their ammonia every day? Participants will be asked to: * Attend three in-person study visits at the clinic. * Measure temperature, heart rate, and blood oxygen every day. * Complete a short survey every day. * Measure ammonia every day. |
MARYLAURA L THOMAS; | 2025-10-06 |
| 109 | The Efficacy and Safety of Chemotherapy and Immune Therapy Combined With Lactobacillus Johnsonii in Patients With Metastatic or Locally Advanced Unresectable or Recurrent EGFR/ALK Wild-type Adenocarcinoma Non-small Cell Lung Cancer (NSCLC), PD-L1 Positive (CPS≥1) Triple-negative Breast Cancer (TNBC) and HER2-negative Gastric or Gastro-oesophageal Junction Adenocarcinoma: A Multicenter, Randomized, Double-blind, Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study plans to enroll 156 patients aged 18-75, who will be randomly divided into two groups to evaluate the clinical efficacy and safety of chemotherapy and immune therapy combined with Lactobacillus johnsonii in patients with various advanced unresectable tumors. This study was divided into three subgroups, … |
SECOND AFFILIATED HOSPITAL SCHOOL OF MEDICINE ZHEJIANG UNIVERSITY | 2025-09-24 |
| 110 | Prospective, Single-cohort, Observational Clinical Study Evaluating The Rate of Achieving SVR12 in Patients With Chronic Hepatitis C Genotype 3 With Fibrosis Stage F0-F2 Who Received Ravidasvir + Sofosbuvir Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test). All participants will be receiving the antiviral drugs ravidasvir and sofosbuvir as part of their regular medical care. Only patients who start this treatment, meet the study’s eligibility criteria, and give written consent for their medical data to be used in research will take part. They will be monitored during their routine clinic visits while receiving the two-drug therapy. After 8 weeks of treatment, … |
PAVEL BOGOMOLOV; | 2026-01-05 |
| 111 | A Phase 1, Open-Label, Single-Dose, Parallel Group, 2-Part Study to Evaluate The Pharmacokinetics of Bepirovirsen in Adult Participants With Severe or Moderate Renal Impairment Compared to Matched Healthy Control Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease. |
JESUS NAVARRO; | 2025-10-15 |
| 112 | Assessment of Foralumab Safety and Modulation of Microglial Activation Evaluated By PET Imaging in Patients With Early Symptomatic Alzheimer’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This phase 2a study will research the safety and tolerability of Foralumab, a human anti-CD3 antibody. An antibody is a molecule secreted by the immune system. These molecules are created to identify a specific pathogen. Previous data on experimental mice has suggested that Foralumab increases the immune system activity in the brain to reduce the inflammation of microglia, … |
GAD A. MARSHALL; | 2026-02-12 |
| 113 | Prevalence of Liver Dysfunction in Paediatric Patients With Congenital Heart Disease: A Cross-Sectional Study at Assiut University Children Hospital PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Liver dysfunction is a well-documented complication in patients with congenital heart disease (CHD). The mechanisms leading to hepatic dysfunction may be multifactorial. Key risk factors for liver dysfunction in CHD include prolonged hypoxemia, high venous pressure, and prolonged duration of heart disease. While global studies have extensively explored this association, the prevalence of liver dysfunction in CHD varies, with studies reporting hepatic fibrosis in 30-40% of Fontan patients, while regional data, particularly from Egypt, remain limited. In this research we aim to determine the prevalence of biochemical and radiological hepatic abnormalities in pediatric CHD patients attending Assiut University Children’s Hospital. |
YASMIN NASSAR MOHAMED AHMED; | 2025-08-27 |
| 114 | An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in patients with relapsed/refractory B-cell malignancies, including B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma. The study is supported by the Presidency of Turkish Health Institutes (TÜSEB) and will be conducted at four centers. This therapy is based on collecting the patient’s own T cells, genetically modifying them in a laboratory to recognize the CD19 antigen, … |
HEALTH INSTITUTES OF TURKEY | 2026-03-30 |
| 115 | Host-Diet-Gut Interaction Post Vegan Diet in Pediatric Autoimmune Hepatitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Pediatric autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH) and overlap syndromes like sclerosing cholangitis, are among the most common chronic liver conditions in the pediatric population. Currently, the treatment for AIH often involves long-term use of immunosuppressive therapy, which carries risks of severe side effects both in the short and long term. Due to these potential adverse effects, there is a critical need to explore alternative therapies that can modulate autoimmunity and potentially reduce or eliminate the dependence on immunosuppressive drugs. Autoimmune diseases, including AIH, typically arise in genetically predisposed individuals after exposure to certain environmental factors, … |
INSTITUTE OF LIVER AND BILIARY SCIENCES INDIA | 2025-08-12 |
| 116 | A Multi-center, Randomized, Open-label, Phase II Study to Evaluate The Efficacy and Safety of BW-20507 Injection Combined With Pegylated Interferon Alfa in Patients With Chronic Hepatitis B Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients |
SHANGHAI ARGO BIOPHARMACEUTICAL | 2026-01-15 |
| 117 | Recall of A Cohort of Subjects in The Mediterranean Area. Monitoring of Liver Diseases (NUTRIHEP 3) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Liver diseases represent a significant public health problem, with a high prevalence and a growing incidence worldwide, and a significant impact on global morbidity and mortality, causing approximately 2 million deaths annually. Deaths are largely attributable to complications of cirrhosis and hepatocellular carcinoma. The most common causes of cirrhosis worldwide are related to viral hepatitis, alcohol, and non-alcoholic fatty liver disease caused by poor dietary habits. Regarding the hepatitis B virus (HBV), the vaccination program, together with the improvement of socioeconomic conditions and greater public awareness, … |
ROSSELLA DONGHIA; | 2025-04-22 |
| 118 | Community Screening for Hepatitis B, C and Delta in The Mongolian Population Living in France PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, … |
FREDERIC HELUWAERT; | 2025-06-26 |
| 119 | Access to Hepatitis C Treatment in Cameroon: Comparison of A Simplified Test and Treat Strategy to A Standard Strategy PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Hepatitis C is a common and potentially serious disease. However, there are treatments that can cure it. That’s why it’s so important to detect the hepatitis C virus (HCV) and treat those affected. Today, many hepatitis C sufferers in Cameroon (and elsewhere) remain untreated. The aim of this research is therefore to evaluate a simplified screening and treatment strategy (developed specifically for the Cameroonian context) in comparison with a standard strategy (based on usual care), in order to improve access to hepatitis C treatment in Cameroon. If the results of this research are positive, … |
ANRS EMERGING INFECTIOUS DISEASES | 2025-08-01 |
| 120 | Immunogenicity and Safety Following In-House Recombinant Hepatitis B (Bio Farma) Vaccine Compared to Registered Hepatitis B Vaccine in Indonesian Population (Phase III) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 3, experimental, randomized, observer-blind, lot to lot consistency study. The primary objective of this study is to assess the protectivity of In-House Recombinant Hepatitis B vaccine 28 days after 3 doses immunization. |
TRISNA WINDIANI; | 2025-06-06 |
| 121 | Multicenter Phase I and II Clinical Study on Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study, titled A Multicenter Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases will investigate Gc Macrophage Activating Factor, a protein derived by enzymatic deglycosylation of vitamin D-binding protein. GcMAF activates macrophages and dendritic cells, modulates M1/M2 profiles, and shows anti-inflammatory effects. Phase I (open-label, dose-escalation) will assess safety, tolerability, and determine a Recommended Dose (RD). Phase II (randomized, double-blind, placebo-controlled) will evaluate efficacy and further confirm safety in a larger patient population with conditions such as moderate rheumatoid arthritis or chronic cystitis, refractory to standard therapies. |
S LAB SOLOWAYS | 2025-12-16 |
| 122 | A Small Prospective Clinical Study on Azvudine Tablets for Treating Chronic Hepatitis B PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Through regular monitoring of viral load, liver function and immune cell activity, the long-term efficacy of Adefovir in controlling HBV is precisely evaluated. By employing a dual mechanism of antiviral action plus immune activation, it offers a novel therapeutic option for achieving clinical cure in chronic hepatitis B. |
ZHIGANG REN; | 2025-12-29 |
| 123 | Optimal Stimulation of Hypo-responders Undergoing IVF: A Prospective, Randomized, Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Stimulation is a key step of in vitro fertilization (IVF). Typically, injectable gonadotropins are used for stimulation, and their dose is individually determined to avoid hypo- as well as hyper-response. Despite the individualization some patients respond with a lower-than-expected number of oocytes. If the low response is unexpected based on the baseline parameters or if an unusually high dose of gonadotropins is needed to achieve a proper response we talk about hypo-response. In such cases if the first treatment fails and a repeat attempt is planned typically even more gonadotropins, … |
PETER KOVACS; | 2025-08-13 |
| 124 | Remedial Mechanisms of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk Between Bile Secretion, Gut Microbiome, and Host Immune Response PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn whether simvastatin alone or in combination with ursodeoxycholic acid (UDCA) can reduce liver fibrosis, inflammation, and gut microbiota imbalance in patients with liver cirrhosis who have achieved viral eradication after hepatitis C or inactive hepatitis B. The main questions the study aims to answer are: Can simvastatin or UDCA reduce biomarkers of liver fibrosis and chronic inflammation? Do these treatments improve gut microbiota composition and bile acid metabolism? Is combination therapy more effective than either drug alone? In this study, … |
CHANG GUNG MEMORIAL HOSPITAL | 2025-08-07 |
| 125 | National Collaborative Centre for Hepatic Regenerative Medicine(NC-CHRM): To Study The Efficacy of Single Vs Repeated Cycle of GCSF+ Darbepoetin in Long Term Transplant Free Management of Patient With Early Decompensated Cirrhosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver’s natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant. |
SHIV KUMAR SARIN; | 2025-08-20 |
| 126 | Clinical Study to Evaluate The Possible Antifibrotic Effect of Zinc Sulphate in Chronic HBV Patient Receiving Anti Viral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy. |
DINA AHMED MOHAMED RAGAI ELREFAEY; | 2025-08-28 |
| 127 | Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: LINC01134, a novel lncRNA, has received increasing attention in cancer research, particularly in hepatocellular carcinoma (HCC). It had been shown that LINC01134 promotes HCC progression by facilitating tumor proliferation, migration, epithelial-mesenchymal transition, oxaliplatin resistance, and radio resistance (Wang et al,2021). Functional experiments revealed that ectopic expression of LINC01134 promotes HCC cell migration and invasion in vitro and HCC liver metastasis and lung metastasis in vivo. Knockdown of LINC01134 represses HCC cell migration and invasion in vitro and HCC liver metastasis and lung metastasis in vivo (Wang et al, … |
ALAA ELSAYED HASSAN; | 2025-08-19 |
| 128 | A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 Vs Bulevirtide for The Treatment of Chronic Hepatitis Delta Infection (AZURE-2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection. |
MIRUM PHARMACEUTICALS | 2026-03-27 |
| 129 | An Open-label, Multicenter Phase II Clinical Trial to Evaluate The Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B Previously Treated With Nucleos (t) Ide Analogues (NA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is an open-label, multicenter phase II clinical study to evaluate the efficacy and safety of AHB-137 injection in participants with CHB previously treated with NA. |
JUNQI NIU; | 2025-08-22 |
| 130 | The Effect of Nursing Care Based on Kolcaba’s Comfort Theory on Pain, Comfort, and Physiological Parameters in Newborns Delivered Vaginally in The Delivery Room PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Newborns may experience pain, stress, and physiological changes during and after birth. Appropriate nursing care during this period can reduce negative effects by increasing the baby’s comfort. Kolbaba’s Comfort Theory aims to provide holistic care by supporting physical, psychological, environmental, and sociocultural comfort. This study aims to investigate the effects of nursing interventions based on Kolcaba’s theory on pain, comfort, crying duration, and physiological parameters (heart rate, respiratory rate, SpO₂, body temperature, etc.) in noenates delivered vaginally. The findings aim to reveal the contribution of comfort-focused approaches in noenates care to clinical outcomes. |
FAHRI AŞKAN; | 2026-02-05 |
| 131 | A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate The Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies. This study is seeking healthy pregnant participants: * aged 49 or younger who can join. * between 24 and 36 weeks of gestation (Gestational age is a medical term used to describe how far along your pregnancy is) * had a fetal ultrasound examination performed with no major fetal abnormalities observed * documented negative for HIV, … |
PFIZER | 2026-02-04 |
| 132 | Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve (ARISE) – A Single-arm Self-controlled Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Diminished Ovarian Reserve (DOR) poses significant challenges to fertility and hormonal health, with limited effective treatments. This prospective, self-controlled clinical study evaluates the safety and efficacy of intraovarian injection of autologous Adipose-Derived Regenerative Cells (ADRCs) to improve ovarian function in reproductive-aged women with DOR. The ARISE trail enrolled 25 women aged \<40 years meeting clinical criteria for DOR, excluding those with severe comorbidities. Autologous adipose tissue was harvested via liposuction, ... |
CYTORI THERAPEUTICS | 2025-08-12 |
| 133 | Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids – A Prospective Registry-based, Cohort Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the effectiveness of low-dose corticosteroids in managing grade 2-3 immune-related hepatitis in cancer patients treated with immune checkpoint inhibitors. It aims to determine whether of 0.5-1miligram per kilogram bodyweight prednisolone is sufficient to manage immune-related hepatitis without the need for dose escalation or additional immunosuppressive therapy. |
ANDREAS SCHMITT; | 2025-09-11 |
| 134 | Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA) Introduction The mode of parenchymal transection in hepatic resection has been a topic of great debate for decades. Many resections have now evolved into laparoscopic , and robotic-assisted procedures to limit morbidity. Morbidity and mortality after hepatic resection has progressively improved over the years due to improved equipment, operative technique \[3\], and anesthetic management. Prior to 1980, mortality rates were reported to be in the 10-20% range with many deaths related to perioperative hemorrhage. Now perioperative mortality has dropped significantly to approximately 5%. The clamp-crush technique, … |
MOHAMED MAHMOUD MOHAMED ELZEER; | 2025-08-27 |
| 135 | Prospective, Open-label, Multicenter Long-term Follow-up Study to Evaluate The Durability of Virologic Response in Participants With Chronic Hepatitis B Previously Treated With AHB-137 Injection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection. |
JINLIN HOU; | 2025-08-28 |
| 136 | BRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV/AIDS PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: BRAVO proposes the establishment of a comprehensive registry of chronic noncommunicable diseases (NCDs), providing crucial data for the formulation of effective health policies for people living with HIV/AIDS (PLWHA). The study will comprise a cross-sectional and longitudinal assessment: the cross-sectional study, will collect on the study allocation sociodemographic data, risk factors related to the main NCDs, physical examination data and samples for determination of biochemical and metabolic parameters; the longitudinal study, lasting 1 year and with the possibility of extension, will follow the participants to identify new diagnoses in the broad spectrum of NCDs. To this end, … |
VICTOR AUGUSTO HAMAMOTO SATO; | 2025-08-12 |
| 137 | A Prospective Study Evaluating Pegylated Interferon Alpha-2b and Nucleos(t)Ide Analogues in Treating Chronic Hepatitis B With or Without Metabolic Dysfunction-Associated Steatotic Liver Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Background Chronic hepatitis B (CHB) is a global health issue that affects a large number of patients. There is currently controversy regarding the treatment strategies for CHB patients with metabolic-associated steatoliver disease (MASLD). Therefore, this study aims to conduct a prospective cohort study to compare the therapeutic effects of pegylated interferon α-2b (Peg IFNα-2b) combined with nucleos(t)ide analogues (NAs) in CHB patients with and without MASLD, and to explore the metabolic improvement effects of Peg IFNα-2b treatment in CHB patients with MASLD. Design This study is a single-center, … |
SHENZHEN THIRD PEOPLE’S HOSPITAL | 2025-07-17 |
| 138 | Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients with chronic diseases, and elderly individuals) who receive their first post-exposure treatment following WHO category II or III rabies exposure. The control group will include 30 healthy adults with similar exposure. Blood samples will be collected at Day 14 and Day 90 after completion of the full vaccination schedule to assess rabies virus neutralizing antibody seroconversion rates and titers. Immunogenicity and antibody persistence will be compared between the two groups. Additionally, … |
FANG HUANG; | 2025-08-13 |
| 139 | The Merits of Implementing MicroRNAs for Diagnosing Hepatocellular Carcinoma Among Hepatitis C Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates a target population of patients with Hepatitis C virus (HCV) infection, including those with complications like liver cirrhosis (LC) and hepatocellular carcinoma (HCC), to investigate the diagnostic utility of a specific panel of microRNAs (miRNAs). The intervention involves quantifying the plasma expression (PE) levels of MiR-21, 1246, 205, 29a-3p, and 497 via PCR and comparing them to healthy controls to determine their efficacy as biomarkers. The primary outcome is to assess the sensitivity, specificity, and overall accuracy of these miRNAs in differentiating HCC from cirrhotic and non-cirrhotic HCV cases, … |
RAAFAT R. MOHAMMED; | 2026-02-12 |
| 140 | End-to-end Digital Transformation for Primary Health Care Performance Management Via Scalable Public Health Empowerment, Research, and Education Sites: A Stepped-Wedge Cluster Randomized Trial PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: SPHERES is a health service research trial in the Indonesian primary care system designed to improve health system performance using a structured data-driven action model. The intervention empowers district health leaders to make data-informed decisions that will enhance outcomes across maternal, child, infectious, and non-communicable disease programs. |
ANURAJ SHANKAR; | 2025-08-15 |
| 141 | A Randomized, Double-blind, Multicenter Phase III Study to Evaluate The Efficacy and Safety of AHB-137 Injection in Participants With HBeAg-negative Chronic Hepatitis B Treated With Nucleos(t)Ide Analogues PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs. |
AUSPER BIOPHARMA | 2025-12-23 |
| 142 | Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection. |
VÉRONQIUE LOUSTAUD-RATTI; | 2025-09-16 |
| 143 | Effects of GPS Tracking on Patient Adherence to Hepatitis C Treatment Among People Experiencing Unsheltered Homelessness PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to determine if GPS tracking can enhance adherence to hepatitis C treatment among patients diagnosed with hepatitis C infection who are also experiencing unsheltered homelessness and receiving street medicine. Research will compare medication adherence among participants randomly assigned to receive standard medical care for Hepatitis C versus the standard medical care for Hepatitis C along with GPS tracking assistance. |
CAMILLO ZAKS; | 2025-08-29 |
| 144 | TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). |
NITIN OHRI; | 2025-09-10 |
| 145 | A Phase 2b Randomized, Open-Label Study to Evaluate The Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection |
VIR BIOTECHNOLOGY | 2026-01-16 |
| 146 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate The Efficacy and Safety of ZM-H1505R (Canocapavir) in Combination With Nucleos(t)Ide Analog(NAs) Compared With NAs Monotherapy in Patients With Chronic Hepatitis B Who Have Received NAs Monotherapy for at Least 12 Months PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs. |
SHANGHAI ZHIMENG BIOPHARMA | 2025-07-31 |
| 147 | A Prospective, Single Center, Randomized, Open Label Phase II Clinical Study: Comparing The Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Target Immunotherapy Treatment PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy. Based on the above research background, we believe that the combination of PD-1 inhibitors and multi-target inhibitors is a promising treatment option for second-line liver cancer. Our study aims to explore the efficacy and safety of trastuzumab monoclonal antibody combined with regorafenib compared to regorafenib monotherapy for second-line treatment of advanced hepatocellular carcinoma after previous target immunotherapy progression. |
TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL | 2025-07-22 |
| 148 | Study of Clinical and Laboratory Predictors of Hepatocellular Carcinoma in Post-HCV Cirrhotic Patients After Sustained Virologic Response PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to identify clinical and laboratory factors that predict the occurrence of hepatocellular carcinoma (HCC) in Egyptian cirrhotic patients after achieving a sustained virologic response (SVR) to hepatitis C virus (HCV) treatment. This is a retrospective, two-center, case-control study that will include 132 cases and 264 controls. Variables to be analyzed include demographics, liver disease status, metabolic comorbidities, lifestyle factors, medications, as well as laboratory parameters and non-invasive scoring systems. |
ZAKARIA SAEED GERGES AWAD; | 2025-08-05 |
| 149 | Clinical Trials of The Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: * Primary objective: The main objective of this study is to assess the efficacy and safety of a sandwich combination therapy in patients who were infected with HBV or have undergone surgery for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). The primary efficacy endpoints are HBsAg seroconversion rate (HBsAg disappearance and HBsAb appearance), and HCC recurrence rate at week 49. Secondary Objective: To evaluate the safety of the HBV sandwich combination therapy through various safety indicators. Safety Indicators as follows: 1) Vital Signs: Monitoring systolic and diastolic blood pressure, pulse, respiration, and body temperature; … |
SHANGHAI ZHONGSHAN HOSPITAL | 2025-07-28 |
| 150 | The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical (Social) Harms Amongst Migrant Populations: A Qualitative Study. (B-SOCIAL) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this qualitative study is to explore the impact of antiviral treatment, or none, for chronic hepatitis B virus on the non-clinical (social) harms experienced by migrant populations living in the UK. Two groups of participants living with hepatitis B virus will be interviewed, those taking the daily treatment, and those not prescribed any treatment. |
KATHRYN E JACK; | 2025-07-16 |
| 151 | Phase 1/2 Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants with CHD. |
GILEAD SCIENCES | 2026-04-03 |
| 152 | A Phase 3 Randomized, Open-Label Study to Evaluate The Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide |
VIR BIOTECHNOLOGY | 2026-03-31 |
| 153 | A Phase 1/2, Dose-finding Study Investigating The Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening. |
ELI LILLY | 2026-03-02 |
| 154 | An Open-Label, Single-Arm, Dose-Escalation Phase I Clinical Trial to Evaluate The Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection Related Papers Related Patents Related Grants Related Experts Highlight: Existing nucleoside analogues (NAs) and interferon therapy for chronic hepatitis B (CHB) have limitations, including drug resistance, low HBsAg clearance rates, and irreversible immunosuppression. Therapeutic vaccines, by activating virus-specific T cells and B cells, hold promise for achieving functional cure (HBsAg clearance + sustained HBV DNA negativity). This study is an open-label, single-arm, dose-escalation Phase I clinical trial. The study population consists of patients with chronic hepatitis B virus infection who have achieved virological stability following standard antiviral therapy. Phase I (dose exploration): three dose groups, … |
JIYAN LIU; | 2025-07-30 |
| 155 | Clinical Performance Evaluation of MagIA In-vitro Diagnostic Medical Device for Multiplex Screening of Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C and Syphilis in Sub-Saharan Africa PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya. |
ANDRE INWOLEY; | 2026-02-02 |
| 156 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Trial of GST-HG141（Neracorvir）for Combination Therapy (add-on) in Patients With Inadequate Response to Antiviral Drugs in Chronic Hepatitis B (CHB) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment. |
FUJIAN AKEYLINK BIOTECHNOLOGY | 2026-01-23 |
| 157 | Intravenous Levetiracetam Versus Intravenous Phenobarbital in Children With Prolonged Seizures Unresponsive to Benzodiazepines PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Convulsive prolonged seizures in children are the most common life-threatening neurological emergencies. The aim of active management of seizure control is to prevent irreversible neuronal damage as early as possible. Although there is evidence of the use of benzodiazepines as the initial management for prolonged seizures, up to a third of patients do not respond to benzodiazepines. Many trials study the rate of seizures control among various second-line antiseizure medications (ASMs) in benzodiazepines unresponsive convulsive prolonged seizures. However, … |
AUNG KYAW MIN; | 2025-08-01 |
| 158 | A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating The Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection. |
ALIGOS THERAPEUTICS | 2026-02-06 |
| 159 | A Multicenter, Open-label, Randomized Controlled Trial Comparing Anti-BCMA CAR-T Cell Therapy Versus Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective study comparing anti-BCMA CAR-T to autologous hematopoietic stem cell transplantation alone in the treatment of newly diagnosed multiple myeloma patients. |
KAI LIN XU，MD; | 2025-07-17 |
| 160 | Lymphatic Osteopathic Manipulative Treatment Protocol for Healthy Individuals: A Crossover Self-Controlled Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to determine whether osteopathic manipulative treatment (OMT) enhances immune system readiness in healthy adults compared to exercise or sham light treatment. Specifically, the goal of this study is to assess circulating immune cells and signaling molecules in the blood in response to these various treatments. It aims to compare: Complete Blood Counts (CBC) and blood immune signaling molecule levels in healthy adults in response to OMT, sham light touch, and exercise, … |
BRIAN LOVELESS; | 2025-07-17 |
| 161 | Efficacy, Safety, and Tolerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug Regimen With BIC/FTC/TAF or DTG/3TC/ABC in Virologically Suppressed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectología, National Medical Center La Raza. The study employs a non-inferiority design with follow-up assessments at 24 and 48 weeks. The study will enroll 156 PLWH aged ≥18 years who are on ART with BIC/FTC/TAF or DTG/3TC/ABC and have maintained virological suppression (HIV-1 RNA \<50 copies/mL) for at least 48 weeks. Participants will be randomized in a 2:1 ratio: 104 to switch to DTG/3TC and 52 to continue their current regimen (control group). |
JOSÉ ANTONIO MATA MARÍN; | 2025-08-22 |
| 162 | Telitacicept in The Treatment of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID): A Prospective, Single-Arm Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This single-center, prospective, single-arm study will evaluate the efficacy and safety of telitacicept in 10 adults with biopsy-proven proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID). Eligible participants (≥18 y, ≥1 g/day proteinuria, eGFR ≥20 mL/min/1.73 m²) will receive 160 mg telitacicept subcutaneously once weekly for 24 weeks after a 12-week run-in on maximally tolerated ACEi/ARB. The primary endpoint is change in 24-hour urine protein from baseline to Week 24. Secondary endpoints include changes in eGFR, urine red-blood-cell count, … |
PEKING UNIVERSITY FIRST HOSPITAL | 2025-08-08 |
| 163 | Evaluation of 200 Mg of Rituximab Every 6 Months As Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis: A Non-inferiority Prospective Randomised Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting joints and causing progressive disability. Current treatment strategies involve conventional disease-modifying anti-rheumatic drugs (csDMARDs) and, in more resistant cases, biologic DMARDs (bDMARDs) such as Rituximab. Rituximab, a monoclonal antibody targeting CD20-positive B cells, is administered as an induction dose followed by maintenance therapy every six months. Standard maintenance dosing consists of 1g infusions, but lower doses may provide equivalent efficacy with fewer side effects. The RADAR trial is a multicenter, prospective, randomized, double-blinded, … |
UNIVERSITY HOSPITAL STRASBOURG FRANCE | 2025-07-23 |
| 164 | Epidemiological Survey and Follow-up of Cardiovascular-Kidney-Metabolic Diseases Among Adults in Shanghai PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants. The study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, … |
TUO LI; | 2025-09-08 |
| 165 | A Phase II/III Seamless Design Clinical Trial of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal recommended dosage of HTS to provide a basis for Phase III confirmatory clinical research. |
XI’AN XINTONG PHARMACEUTICAL RESEARCH | 2025-10-02 |
| 166 | Fuzheng Huayu Tablets Reduce The Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1. Participants will be randomly assigned to the two groups using a stratified block randomization method at the central level. The Fuzheng Huayu group (Fuzheng Huayu tablets combined with conventional antiviral therapy) and the placebo group (placebo combined with conventional antiviral therapy) will be treated for 48 weeks, … |
ZHIYUN YANG; | 2025-06-12 |
| 167 | Phase 1, Open Label Study to Evaluate Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn about the safety and tolerability of NTR-101 in adult participants suffering from acute alcohol-associated hepatitis (AH). The drug is intended for use in the treatment of AH where the presence of specific strains of E. faecalis play a contributing role. The main questions it aims to answer are: Are multiple doses of NTR-101 in participants with acute AH safe and well tolerated? What medical problems do participants have when taking NTR-101? Researchers will administer the drug and monitor participants in an inpatient center. Participants will: Be administered multiple ascending dose frequencies of NTR-101 every day for 7 days. Stay in the clinic for 9 days (7 days of treatment) and present to clinic once every week for checkups and tests for 35 days. Keep a diary of their symptoms until the checkups and tests are completed. |
TAREK HASSANEIN; | 2025-05-22 |
| 168 | Fatigue in Cerebral Palsy: An EEG- and FDG-PET-based Study of Brain Activity and Its Correlation With Fatigue PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Persons with cerebral palsy (CP) commonly suffer from fatigue. Fatigue is an important cause of their reduced participation in work or social life. Traditionally, CP-related fatigue has been viewed as related to the person’s motor impairment. This view causes habilitation efforts to focus on muscle function. We hypothesize that the feeling of being fatigued must involve the activity of a specific, but un-identified, … |
BJØRNAR HASSEL; | 2025-12-19 |
| 169 | Protocol for A Superiority Randomized Controlled Trial of A Group-Based Fatigue Management Program Versus Standard Information to Improve Self-Efficacy in Energy Conservation in Parkinson’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This protocol describes a randomized, controlled, parallel-group, trial evaluating the effectiveness of a group-based fatigue management program for people with Parkinson’s disease. The study will be conducted in Italy, with participant recruitment planned to begin on July 1st, 2025. The primary sponsor is the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Child Health (DINOGMI) at the University of Genoa, Italy. No external sources of monetary or material support have been declared. The study has received ethical approval from the University of Genoa’s Research Ethics Committee (Comitato Etico per la Ricerca di Ateneo – CERA), under protocol number 2025.36, … |
ELISA PELOSIN; | 2025-10-07 |
| 170 | Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects. |
SARFEZ PHARMACEUTICALS | 2026-03-06 |
| 171 | Effects Of Pulsatile and Non-Pulsatile Cardiopulmonary Bypass Flow On Predictors Of Outcome After Coronary Artery Bypass Graft Surgery PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In cardiac operations, high values of blood lactate have been associated with bad outcomes if detected both during CPB and at the arrival in the intensive care unit (ICU) in adult patients. Many studies highlighted the potential role of hyperlactatemia on admission to the ICU as a marker for adverse outcome, and one study linked hyperlactatemia during CPB with postoperative morbidity and mortality. Evidence that both CENTRAL VENOUS SATURATION (ScVO2) and blood lactates during CPB are potential early predictors of morbidity and mortality in adult cardiac operations are still lacking. |
ISLAM ELBARDAN; | 2025-06-24 |
| 172 | Methylene Blue Treatment of Chronic Hepatitis B Virus Infection: A Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease. Diagnosis and treatment depend on the stage of infection, the degree of liver inflammation, and the progression of fibrosis. Patients with HBeAg-positive or -negative hepatitis are usually treated with nucleos(-t)ide analogues. This treatment inhibits HBV reverse transcriptase and reduces viral replication, … |
ANDREAS CERNY; | 2025-06-27 |
| 173 | Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in The Democratic Republic of The Congo PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection. The study will be conducted in Boende, Tshuapa Province, DRC. A total of 359 maternal participants, aged 16 to 35 and in their second or third trimester of pregnancy, will be enrolled. Participants will be randomly assigned to receive two subcutaneous doses of the MVA-BN vaccine, given 28 days apart, … |
JEAN-PIERRE VAN GEERTRUYDEN; | 2026-01-30 |
| 174 | Massachusetts HIV and Justice Involved Populations Research Network PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This pilot feasibility study represents part 3 of a larger R61 study, where the investigators will follow a cohort about their experiences with human immunodeficiency virus (HIV) testing. This project aims to assess the effectiveness of an intervention at two jail sites in the Boston area: South Bay House of Corrections and Nashua Street Jail implemented in January of 2025 that is aimed at improving HIV testing practices and HIV treatment in those carceral facilities. This implementation was developed independently of the investigators’ study activities. The jails worked to develop changes in their electronic health record to offer HIV testing at various points in their intake and physical exam process. HIV care was not well-integrated with the jails’ existing intake and healthcare administration systems and medications for opioid use disorder (MOUD) program. The investigators will evaluate the intervention the jails developed to address these issues. The outcomes of interest are more implementation than effectiveness outcomes. The primary goal of this study is to identify existing barriers in the carceral healthcare setting that prevent the improvement of HIV testing and treatment. |
ALYSSE WURCEL; | 2025-07-30 |
| 175 | Long-term Immunogenicity of Lived-attenuated Hepatitis A Virus Vaccine Among Healthy Thai Children and Adolescents PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Hepatitis A virus (HAV) remains a common infection among Thai children. Two types of HAV vaccines are available in Thailand: an inactivated vaccine (I-HAV, administered in two doses 6 months apart) and a live-attenuated vaccine (L-HAV, administered as a single dose). However, neither vaccine is currently included in Thailand’s Expanded Programme on Immunization (EPI). In 2024, a randomized, active-controlled, open-label, … |
TAVITIYA SUDJARITRUK; | 2025-06-24 |
| 176 | Out-of-hospital Screening of Patients With Significant Hepatic Fibrosis or Cirrhosis and Viral Hepatitis B and C PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Regardless of its etiology (chronic hepatitis B or C, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue. Cirrhosis is a chronic disease and can get complicated by liver cancer, digestive hemorrhage, or liver failure, which are responsible for morbidity and mortality. In France, cirrhosis prevalence is estimated at 700,000 patients and induce 16,000 deaths per year (10,000 liver cancer and 6,000 liver decompensation). In Ile-de-France area, cirrhosis prevalence is estimated at 130,000 cases, … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2025-06-24 |
| 177 | TherVacB – A Multi-center Phase 1b/2a Trial to Assess Safety, Tolerability and Immunogenicity of A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is an open-label, ascending dose phase 1b/2a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine in patients with chronic HBV who are virally suppressed with oral anti-viral therapies. |
MICHAEL HOELSCHER; | 2025-07-25 |
| 178 | MINMON-J: An Effectiveness Implementation Pilot Study Evaluating A Low-barrier Hepatitis C Treatment Model in A Jail Setting PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial. The study asks: * Can a simplified, low-barrier HCV treatment program work in a jail setting? * Do participants finish treatment and get cured using this approach? All participants will receive a 12-week course of the HCV medication sofosbuvir/velpatasvir (Epclusa). If they are released before completing treatment, … |
JUSTIN BERK; | 2026-02-27 |
| 179 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, … |
PREMAL LULLA; | 2025-11-03 |
| 180 | Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures Outside The Walls By Dual Screening Method RTDs and FibroScan® PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The Scanvir concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient’s health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a test, treat and cure strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers. |
MARILYNE DEBETTE-GRATIEN; | 2025-08-14 |
| 181 | An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for The Treatment of Chronic Hepatitis C Virus (HCV) Infection in A Phase 3 Randomized, Controlled, Open-label Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV. |
ATEA PHARMACEUTICALS | 2026-01-20 |
| 182 | Optimal Timing of Hepatitis B Vaccination After Transplants: A Randomized Clinical Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status. |
INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINA | 2025-03-21 |
| 183 | A Real-World Study on Reducing The Risk of Liver Cancer in Chronic Hepatitis B Patients With A Family History of HBV-Related Liver Cancer PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, multicenter, real-world cohort study designed to compare the long-term outcomes of chronic hepatitis B patients with a family history of HBV-related hepatocellular carcinoma (HCC) who receive PEG IFNα-2b combined with nucleos(t)ide analogues or nucleos(t)ide monotherapy. The primary endpoint is the incidence rate of HCC, and secondary endpoints include the rate of HBsAg seroclearance, changes in liver fibrosis, and survival rates. The study will last for 5 years and enroll approximately 15,000 patients, aiming to provide evidence-based optimization for CHB treatment regimens. |
GUIQIANG WANG; | 2025-06-05 |
| 184 | A Prospective, Multi-national, Multi-center, Open-label, Randomized, Active Controlled, Parallel Group, Operationally Seamless Phase II/III Clinical Study to Evaluate The Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, A Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus (Inactivated)-Haemophilus Influenzae Type B Conjugate (DTwP-HepB-IPV-Hib) Vaccine, Compared to Co-administration of DTwP-HepB-Hib Vaccine and IPV Vaccine in Healthy Infants at 6-, 10-, and 14-week of Age As Primary Series PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate immunogenicity, safety and lot-to-lot consistency of LBVD in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants |
LG CHEM | 2025-07-03 |
| 185 | A Randomized, Open-Label, Multicenter Phase II Study to Evaluate The Efficacy and Safety of AHB-137 Injection in Combination With Hepatitis B Vaccine or Pegylated Interferon Α-2b (Peg-IFN) in Participants With HBeAg-Negative Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogue (NAs) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs. |
AUSPER BIOPHARMA | 2025-11-26 |
| 186 | Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Thai Children and Adolescents Lacking Protective Antibody Levels After A Single Dose of Live-attenuated Hepatitis A Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Hepatitis A virus (HAV) remains a common infection in Thai children. Two HAV vaccines are available: inactivated vaccine (I-HAV, 2 doses) and live-attenuated vaccine (L-HAV, single dose), but neither is included in Thailand’s national immunization program. Our previous randomized, active-controlled, open-label, non-inferiority trial trial found that some participants remained seronegative after one L-HAV dose (anti-HAV IgG \<1 S/CO) (preliminary data). This study aims to evaluate the immunogenicity and safety of an additional dose of I-HAV in healthy Thai children and adolescents who did not develop protective antibody levels after a single dose of L-HAV. |
TAVITIYA SUDJARITRUK; | 2025-06-17 |
| 187 | Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada: A Multilevel Implementation Science Study of Clinical Processes, Barriers, Facilitators and Implementation Strategies PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The SCALE-POCT study is a national initiative designed to provide robust evidence for scaling up point-of-care hepatitis C testing for key populations. The study seeks to map current hepatitis C clinical processes, identify barriers and facilitators to implementation, and co-design practical tools and strategies in partnership with stakeholders. A major obstacle to hepatitis C elimination and increasing treatment uptake is the current multi-step diagnostic process, which leads to loss to follow-up and treatment delays, particularly among high-risk groups such as people who inject drugs. Point of-care hepatitis C antibody tests (results: 5-20 mins) and RNA tests (results: 60 mins), … |
GUILLAUME FONTAINE; | 2025-07-31 |
| 188 | An Exploratory Clinical Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Diseases PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc. Aproximately 6-12 patients aged 18-65 will receive a single infusion of YTS109 cells (1.5×10⁶ cells/kg). The main purpose of exploratory clinical research is to explore the efficacy and safety of YTS109 cell and the lymphodepletion regimen. The primary endpoint is observations of types, severity, and frequency of adverse events (AEs) and efficacy assessment. This single-arm, open-label trial will enroll patients across Chinese People’s Liberation Army (PLA) General Hospital. |
CHINA IMMUNOTECH BEIJING BIOTECHNOLOGY | 2025-07-14 |
| 189 | The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients —— Risk Early Warning and Follow-up Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic chronic hepatitis-liver cirrhosis-HCC progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet effective monitoring strategies remain lacking. Current early diagnosis relies on the combination of imaging techniques and serum alpha-fetoprotein (AFP), but AFP measurements are frequently confounded by pregnancy and liver diseases, resulting in suboptimal sensitivity and specificity. In recent years, … |
ZHONGTIAN PENG; | 2025-08-29 |
| 190 | Effect of Acupressure on Sleep Quality in Hemodialysis Patients: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aimed to evaluate the effects of acupressure applied to patients receiving hemodialysis treatment on sleep quality. |
DIDEM LAFCI; | 2025-02-26 |
| 191 | Neuropathy in Waldenström’s Macroglobulinemia: Pathophysiology, Prognosis and Treatment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Neuropathy severely reduces patients’ quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs. Given the diverse origins of neuropathy, it is critical to identify its specific causes, particularly when effective treatments are available. Neuropathy is a frequent morbidity in Waldenström’s macroglobulinemia (WM), … |
MORTEN MÜLLER AAGAARD; | 2025-09-08 |
| 192 | BCG2-DTP3: Providing BCG Revaccination With The Third Dose of Diphtheria-tetanus-pertussis Vaccine to Improve Female Survival in Africa PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Studies in low-income countries show that vaccines can have important non-specific effects on other infections. Live BCG vaccine can train the immune system and reduce susceptibility to unrelated infections. In contrast, non-live diphtheria-tetanus-pertussis-containing (DTP) vaccine enhances susceptibility in females: DTP vs no DTP is associated with 2-fold higher mortality, and in DTP-vaccinated children, … |
CHRISTINE STABELL BENN; | 2025-06-12 |
| 193 | Proton Therapy Versus Photon Therapy for The Treatment of Nasopharyngeal Carcinoma: A Prospective, Open-Label, Multicenter, Phase III Non-Inferiority Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, open-label, multicenter, cohort, phase III non-inferiority clinical trial comparing proton therapy with photon radiotherapy for nasopharyngeal carcinoma. It intends to enroll histologically confirmed newly diagnosed nasopharyngeal carcinoma patients without distant metastasis (M0). Through a prospective 1:1 matched cohort study design, patients will be divided into the intensity-modulated proton therapy (IMPT) group and the intensity-modulated radiation therapy (IMRT) group. Systemic treatment regimens are formulated according to clinical guidelines. |
MAN HU; | 2025-06-03 |
| 194 | Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure: Safety, Efficacy, and Treatment Schedule Exploration PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this Phase I clinical trial is to evaluate the safety and efficacy of combining the QH-1A bioartificial liver device with mesenchymal stem cells（MSCs） for blood purification in treating patients with acute-on-chronic liver failure, … |
LIANG PENG; | 2025-05-30 |
| 195 | A Multicenter, Prospective, Open-label, Non-inferiority Randomized Controlled Study on The Efficacy of Tenofovir Alafenamide Fumarate Vs. Tenofovir Disoproxil Fumarate in Preventing Mother-to-Child Transmission of Hepatitis B Virus in Pregnant Women With High Viral Loads PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of this study is to compare the mother-to-infant transmission rates of hepatitis B between pregnant women receiving treatment with tenofovir alafenamide and those receiving treatment with tenofovir disoproxil fumarate, after administering the hepatitis B vaccine and hepatitis B immunoglobulin to their infants at birth. Investigators define the mother-to-infant transmission rate of hepatitis B as the proportion of infants who are HBsAg positive and have serum HBV DNA \>20 IU/mL at 28 weeks of age among all live births in the experimental group. Additionally, … |
CALVIN Q.PAN; | 2025-05-07 |
| 196 | Pooled Human Plasma Vs Crystalloid in The Management of Children Undergoing Instrumented Spinal Fusion for Scoliosis: A Double-Blind, Randomized Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: OCTAGON trial is a randomized, double-blinded, parallel-group non-inferiority multicenter (Helsinki and Turku University Hospitals, Finland) clinical trial according to CONSORT criteria. 194 adolescents with idiopathic (major curve \> 45 degrees) or neuromuscular scoliosis (major curve \> 50 degrees) are enrolled for the OCTAGON trial comparing pooled human plasma (Octaplas, 10mL/kg, active management) vs. Plasmalyte (10 mL/kg, placebo) before incision as part of the normal intraoperative fluid therapy. Data is collected at baseline and at each follow-up until a minimum of 2-year follow-up. Outcomes Outcomes for the OCTAGON trial include 1) intraoperative blood loss (in mL, … |
MATTI AHONEN; | 2025-05-07 |
| 197 | A Multicenter, Prospective, Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, prospective, real-world study. The study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced patients. The effectiveness and safety of different treatment strategies will be evaluated in children aged 1-12 years with treatment-naive and treatment-experienced chronic hepatitis B (CHB) and chronic HBV infection. |
FU-SHENG WANG; | 2025-04-29 |
| 198 | A Multicenter, Open-Label, Randomized, Controlled Study of Autologous Stem Cell Transplantation Followed By Anti-BCMA CAR-T Therapy Versus ASCT Alone in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective study comparing autologous hematopoietic stem cell transplantation followed by anti-BCMA CAR-T to autologous hematopoietic stem cell transplantation alone in the treatment of newly diagnosed multiple myeloma patients. |
KAI LIN XU，MD; | 2025-05-09 |
| 199 | Efficacy and Safety of Pegylated Interferon Therapy in Chronic Hepatitis B Patients After Discontinuation of Antisense Oligonucleotide or Small Interfering RNA: A Prospective, Adaptive, Open-label, Randomized Controlled Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to compare sequential PEG-IFNα therapy strategies in chronic hepatitis B (CHB) patients previously treated with ASO/siRNA. The main questions it aims to answer are: 1. Does sequential PEG-IFNα therapy (vs. deferred/no treatment) improve HBsAg clearance rates? 2. What are the HBsAg clearance and relapse rates after 24 weeks of PEG-IFNα therapy? 3. Is intermittent PEG-IFNα therapy as effective and safe as continuous therapy? Researchers will compare: • Group A (immediate 24-week PEG-IFNα + 24-week follow-up) vs. Group B (24-week observation + 24-week PEG-IFNα) in Phase 1 to see if sequential PEG-IFNα therapy will improve HBsAg loss rate . Researchers will describe: * The response rate of IFN treatment in non-responders (HBsAg-positive) in Phase 2. * The relaspe rate of responders (HBsAg-negative). Participants will: Phase 1 (0-48 weeks): * Group A: Receive PEG-IFNα for 24 weeks, followed by 24-week treatment-free follow-up. * Group B: Undergo 24-week observation, then receive PEG-IFNα for 24 weeks. Phase 2 (48-96 weeks): * HBsAg-positive at week 48 patients either from group A or group B : Receive 24-week PEG-IFNα therapy, followed by 24-week follow-up. * HBsAg-negative at week 48 patients either from group A or group B: Enter 24-week follow-up without treatment. All participants will undergo: • HBsAg quantification, HBV DNA, liver function, and safety monitoring (every 12 weeks). |
WEN-HONG ZHANG; | 2025-04-11 |
| 200 | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Anlotinib Combined With Benmelstobart in The First-line Treatment of Advanced Pheochromocytoma/Paraganglioma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: There is currently no standard first-line treatment for stage PPGL, and the 5-year survival rate of patients with advanced pheochromocytoma/paraganglioma (PPGL) is low, ranging from 30% to 60%. At present, several domestic teams have carried out clinical studies on the treatment of advanced PPGL with good efficacy. In the early stage, our center used anrotinib to treat advanced PPGL, and the overall effective rate reached 44%. In the early stage, our team used anrotinib combined with PD-1 monoclonal antibody to treat advanced PPGL patients. The effective rate reached 66% (2/3). Therefore, … |
ZHOU FANGJIAN; | 2025-04-29 |